• Abe D, Sakaki T, Kusudo T, Kittaka A, Saito N, Suhara Y, Fujishima T, Takayama H, Hamamoto H, Kamakura M, Ohta M, Inouye K. Metabolism of 2alpha-propoxy-1alpha-,25-dihydroxyvitamin D3 and 2alpha-(3-hydroxypropoxy)-1alpha,25-dihydroxyvitamin D3 by human CYP27A1 and CYP24A1. Drug Metab. Dispos. 33: 778-784 (2005). *

• Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, Bouhnik Y, Coffin B, Allez M, Lamarque D, Chaussade S. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5: 1184-1189 (2007).

• Abitbol V, Mary JY, Roux C, Soule JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S; Groupe D'etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment. Pharmacol. Ther. 16: 919-927 (2002). *

• Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J. Clin. Gastroenterol. 40: 55-63 (2006).

• Ackert-Bicknell C, Rosen C. The genetics of PPARG and the skeleton. PPAR Res. 2006: 93258 (2006). *

• Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm. Bowel Dis. 5: 200-211 (1999).

• Adam O, Fasse S, Ditrich O. Diet in rheumatic disease. Z. Rheumatol. 68: 549-558 (2009).

• Agardh D, Bjorck S, Agardh CD, Lidfeldt J. Coeliac disease-specific tissue transglutaminase autoantibodies are associated with osteoporosis and related fractures in middle-aged women. Scand. J. Gastroenterol. 44: 571-578 (2009). *

• Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci. 1030: 434-441 (2004). *

• Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H. TNF blockade: an inflammatory issue. Ernst Schering Res. Found. Workshop 56: 161-186 (2006).

• Ahmed SF, Horrocks IA, Patterson T, Zaidi S, Ling SC, McGrogan P, Weaver LT. Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. J. Pediatr. Gastroenterol. Nutr. 38: 276-280 (2004). *

• Ahn KS, Aggarwal BB. Transcription factor NF-kappaB: a sensor for smoke and stress signals. Ann. N. Y. Acad. Sci. 1056: 218-233 (2005). *

• Ahn KS, Sethi G, Chaturvedi MM, Aggarwal BB. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway. Int. J. Cancer 123: 1733-1740 (2008). *

• Ahuja SS, Zhao S, Bellido T, Plotkin LI, Jimenez F, Bonewald LF. CD40 ligand blocks apoptosis induced by tumor necrosis factor alpha, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4. Endocrinology 144: 1761-1769 (2003). *

• Akhter MP, Jung LK. Decreased bone strength in HLA-B27 transgenic rat model of spondyloarthropathy. Rheumatology (Oxford) 46: 1258-1262 (2007). *

• Al-Oanzi ZH, Tuck SP, Mastana SS, Summers GD, Cook DB, Francis RM, Datta HK. Vitamin D-binding protein gene microsatellite polymorphism influences BMD and risk of fractures in men. Osteoporos. Int. 19: 951-960 (2008). *

• Alaedini A, Green PH. Narrative review: celiac disease: understanding a complex autoimmune disorder. Ann. Intern. Med. 142: 289-298 (2005). *

• Ali T, Lam D, Bronze MS, Humphrey MB. Osteoporosis in inflammatory bowel disease. Am. J. Med. 122: 599-604 (2009). *

• Alibek K, Grechanyi L, Klimenko T, Pashkova A. Fifth revolution in medicine: on the role of infections in pathogenesis of aging and chronic diseases. Lik. Sprava. 1-2: 3-30 (2008).

• Alley RA, Chen EL, Beyer TD, Prinz RA. Does homocysteine contribute to bone disease in hyperparathyroidism? Am. J. Surg. 195: 374-377 (2008). *

• Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patients - extended report. Rheumatology (Oxford) 46: 1185-1190 (2007). *

• Almeida M, Ambrogini E, Han L, Manolagas SC, Jilka RL. Increased lipid oxidation causes oxidative stress, increased PPARgamma expression and diminished pro-osteogenic Wnt signaling in the skeleton. J. Biol. Chem. 284: 27438-27448 (2009). *

• Alnounou M, Munoz SJ. Nutrition Issues In Gastroenterology, Series #37. Nutrition concerns of the patient with primary biliary cirrhosis or primary sclerosing cholangitis. [http://www.healthsystem.virginia.edu/internet/digestive-health/nutritionarticles/April2006.pdf] Practical Gastroenterology April 2006: 92-100 (2006). *

• Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pediatrics. Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1: 23-32 (2009).

• Alpers DH. The role of nutritional deficiency in the osteopenia and osteoporosis of gastrointestinal diseases. Curr. Opin. Gastroenterol. 18: 203-208 (2002).

• Alsaadi G, Quirynen M, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J. Clin. Periodontol. 34: 610-617 (2007).

• Alsaadi G, Quirynen M, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of late oral implant loss. Clin. Oral Implants Res. 19: 670-676 (2008).

• Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57 (2008).

• Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S. The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J. Neurol. Sci. 276: 41-44 (2009).

• Ambrogini E, Toraldo G, Marcocci C. Post-menopausal osteoporosis: is it an autoimmune disease? J. Endocrinol. Invest. 28: S43-S47 (2005).

• American Gastroenterological Association. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 125: 937-940 (2003). *

• Anca I, Stanescu-Popp A, Arama V, Duta D, Alexe G, Colcer F. Celiac disease: diagnostic criteria and impact of gluten free diet - patients' perspective. Rev. Med. Chir. Soc. Med. Nat. Iasi. 113: 351-355 (2008).

• Anderson RP. Coeliac disease. Aust. Fam. Physician 34: 239-242 (2005). *

• Anderson RP. Coeliac disease: current approach and future prospects. Intern. Med. J. 38: 790-799 (2008). *

• Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand. J. Gastroenterol. 32: 1247-1255 (1997).

• Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD. Oral budesonide in the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 2333-2337 (2000). *

• Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31: 318-323 (2000). *

• Angulo P, Therneau TM, Jorgensen A, DeSotel CK, Egan KS, Dickson ER, Hay JE, Lindor KD. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. J. Hepatol. 29: 729-735 (1998). *

• Arabi A, Khoury N, Birbari A, Zahed L, El-Hajj Fuleihan G. Regression of skeletal manifestations of hyperparathyroidism with oral vitamin D. J. Clin. Endocrinol. Metab. 91: 2480-2483 (2006). *

• Arabi A, Mahfoud Z, Zahed L, El-Onsi L, El-Hajj Fuleihan G. Effect of age, gender and calciotropic hormones on the relationship between vitamin D receptor gene polymorphisms and bone mineral density. Eur. J. Clin. Nutr. Feb 10 [Epub ahead of print] (2010). *

• Arabi A, Zahed L, Mahfoud Z, El-Onsi L, Nabulsi M, Maalouf J, Fuleihan GE. Vitamin D receptor gene polymorphisms modulate the skeletal response to vitamin D supplementation in healthy girls. Bone 45: 1091-1097 (2009). *

• Arden NK, Cooper C. Osteoporosis in patients with inflammatory bowel disease. Gut 50: 9-10 (2002). *

• Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig. Liver Dis. 40 Suppl. 2: S253-S259 (2008).

• Ardoin SP, Schanberg LE. The management of pediatric systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 1: 82-92 (2005). *

• Armagan O, Uz T, Tascioglu F, Colak O, Oner C, Akgun Y. Serological screening for celiac disease in premenopausal women with idiopathic osteoporosis. Clin. Rheumatol. 24: 239-243 (2005). *

• Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann. Rheum. Dis. 66: 1137-1142 (2007). *

• Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig. Dis. Sci. Dec 4 [Epub ahead of print] (2009). *

• Atas A, Cakmak A, Soran M, Soker M, Varma M. Severe osteoporosis and high level TSH in a child before the diagnosis of acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 31: 588-591 (2009).

• Atkinson MJ, Vido I, Keck E, Hesch RD. Hepatic osteodystrophy in primary biliary cirrhosis: a possible defect in Kupffer cell mediated cleavage of parathyroid hormone. Clin. Endocrinol. (Oxf.) 19: 21-28 (1983).

• Babyn P, Doria AS. Radiologic investigation of rheumatic diseases. Pediatr. Clin. North Am. 52: 373-411 (2005).

• Bagur A, Mautalen C, Findor J, Sorda J, Somoza J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif. Tissue Int. 63: 385-390 (1998). *

• Ballester I, Daddaoua A, Lopez-Posadas R, Nieto A, Suarez MD, Zarzuelo A, Martinez-Augustin O, de Medina FS. The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats. Br. J. Pharmacol. 151: 206-215 (2007). *

• Ban Y, Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid 10: 475-480 (2000).

• Ban Y, Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid 10: 375-380 (2000).

• Ban Y, Taniyama M, Ban Y. Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population. J. Clin. Endocrinol. Metab. 85: 4639-4643 (2000). *

• Ban Y, Taniyama M, Tozaki T, Tomita M, Ban Y. Estrogen receptor alpha dinucleotide repeat polymorphism in Japanese patients with autoimmune thyroid diseases. BMC Med. Genet. 1: 1 (2000). *

• Ban Y, Tozaki T, Taniyama M, Tomita M, Ban Y. Lack of association between estrogen receptor beta dinucleotide repeat polymorphism and autoimmune thyroid diseases in Japanese patients. BMC Med. Genet. 2: 1 (2001). *

• Bannwarth B. Drug-induced musculoskeletal disorders. Drug Saf. 30: 27-46 (2007).

• Bardella MT, Bianchi ML,Teti A. Chronic inflammatory intestinal diseases and bone loss. Gut 54: 1508 (2005). *

• Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *

• Barr R, Macdonald H, Stewart A, McGuigan F, Rogers A, Eastell R, Felsenberg D, Gluer C, Roux C, Reid DM. Association between vitamin D receptor gene polymorphisms, falls, balance and muscle power: results from two independent studies (APOSS and OPUS). Osteoporos. Int. Jul 24 [Epub ahead of print] (2009). *

• Barritt AS 4th, Zacks SL, Rubinas TC, Herfarth HH. Oral budesonide for the therapy of post-liver transplant de novo inflammatory bowel disease: a case series and systematic review of the literature. Inflamm. Bowel Dis. 14: 1695-1700 (2008). *

• Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment. Pharmacol. Ther. 18: 1121-1127 (2003). *

• Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J. Gastroenterol. 12: 5680-5686 (2006). *

• Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am. J. Gastroenterol. 100: 2254-2261 (2005). *

• Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin. Liver Dis. 21: 437-451 (2001).

• Becker A, Fischer R, Schneider M. Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus. Z. Rheumatol. 60: 352-358 (2001).

• Beltinger J, Froehlich F. Patients with inflammatory bowel disease in specialist gastroenterology practice: a prospective survey. Schweiz. Rundsch. Med. Prax. 94: 459-465 (2005).

• Ben Hamida KS, Serghini M, Ksontini I, Kedadi H, Ben Yaghlene L, Bougassas W, Dougui MH. Bone loss owing to inflammatory bowel disease: prospective study about 50 cases. Tunis. Med. 87: 144-148 (2009).

• Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, Podda M, Battezzati PM. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J. Clin. Gastroenterol. 42: 306-311 (2008).

• Benzinger P, Alscher DM. Untreated homocystinuria in adulthood. Dtsch. Med. Wochenschr. 130: 2439-2443 (2005).

• Bergasa NV. Management of complications of cholestasis: pruritus, fatigue and bone disease. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 54. October 15-16 (2003). *

• Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020 (2004). *

• Bergmann MM, Jacobs EJ, Hoffmann K, Boeing H. Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire. Eur. J. Epidemiol. 19: 411-416 (2004).

• Bernstein CN. Inflammatory bowel diseases as secondary causes of osteoporosis. Curr. Osteoporos. Rep. 4: 116-123 (2006).

• Bernstein CN. Osteoporosis in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 152-156 (2006).

• Bernstein CN. Is hyperhomocysteinemia associated with osteoporosis in patients with Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 550-551 (2007). *

• Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 4: 513-516 (2002).

• Bernstein CN. Osteoporosis and other complications of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18: 428-434 (2002).

• Bernstein CN, Leslie WD. Osteoporosis and inflammatory bowel disease. Aliment. Pharmacol. Ther. 19: 941-952 (2004). *

• Bernstein CN, Leslie WD. Therapy insight: osteoporosis in inflammatory bowel disease - advances and retreats. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 232-239 (2005). *

• Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm. Bowel Dis. 11: 325-330 (2005). *

• Bernstein CN, Seeger LL, Anton PA, Artinian L, Geffrey S, Goodman W, Belin TR, Shanahan F. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Aliment. Pharmacol. Ther. 10: 777-786 (1996).

• Bertoli AM, Alarcon GS, Calvo-Alen J, Fernandez M, Vila LM, Reveille JD. Systemic lupus erythematosus in a multiethnic US cohort: clinical features, course, and outcome in patients with late-onset disease. Arthritis Rheum. 54: 1580-1587 (2006). *

• Bhattacharya A, Rahman M, Banu J, Lawrence RA, McGuff HS, Garrett IR, Fischbach M, Fernandes G. Inhibition of osteoporosis in autoimmune disease prone MRL/Mpj-Faslpr mice by n-3 fatty acids. J. Am. Coll. Nutr. 24: 200-209 (2005). *

• Bhattacharya A, Rahman M, Sun D, Fernandes G. Effect of fish oil on bone mineral density in aging C57BL/6 female mice. J. Nutr. Biochem. 18: 372-379 (2007). *

• Biagini MR, Tozzi A, Bongini E, Capanni M, Galli A, Milani S, Surrenti C. Association of plasma homocysteine with bone mineral density in postmenopausal women with osteoporosis or osteopenia affected by primary biliary cirrhosis. J. Clin. Gastroenterol. 41: 635 (2007).

• Bianchi ML. How to manage osteoporosis in children. Best Pract. Res. Clin. Rheumatol. 19: 991-1005 (2005).

• Bianchi ML, Bardella MT. Bone in celiac disease. Osteoporos. Int. 19: 1705-1716 (2008). *

• Bilic-Curcic I, Milas-Ahic J, Smolic M, Smolic R, Mihaljevic I, Tucak-Zoric S. Urolithiasis and osteoporosis: clinical relevance and therapeutic implications. Coll. Antropol. 33 Suppl. 2: 189-192 (2009).

• Binkley N, Novotny R, Krueger D, Kawahara T, Daida YG, Lensmeyer G, Hollis BW, Drezner MK. Low vitamin D status despite abundant sun exposure. J. Clin. Endocrinol. Metab. 92: 2130-2135 (2007). *

• Birlea SA, Costin GE, Norris DA. Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. Curr. Drug Targets 9: 345-359 (2008).

• Bitetto D, Fabris C, Falleti E, Fornasiere E, Fumolo E, Fontanini E, Cussigh A, Occhino G, Baccarani U, Pirisi M, Toniutto P. Vitamin D and the risk of acute allograft rejection following human liver transplantation. Liver Int. Oct 22 [Epub ahead of print] (2009). *

• Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 40: 228-233 (1997). *

• Bjelakovic G, Beninati S, Pavlovic D, Kocic G, Jevtovic T, Kamenov B, Saranac LJ, Bjelakovic B, Stojanovic I, Banic J. Glucocorticoids and oxidative stress. J. Basic Clin. Physiol. Pharmacol. 18: 115-127 (2007).

• Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 356: 1809-1822 (2007). *

• Blagosklonny MV. Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition. Cell Cycle 5: 2087-2102 (2006). *

• Blahos J. Relation between osteoporosis and celiac disease. Vnitr. Lek. 53: 1241-1242 (2007).

• Blaney GP, Albert PJ, Proal AD. Vitamin D metabolites as clinical markers in autoimmune and chronic disease. Ann. N. Y. Acad. Sci. 1173: 384-390 (2009). *

• Bogdanos D, Vergani D, Mieli-Vergani G. Overlap syndromes from pediatrics to adulthood. J. Gastroenterol. Hepatol. 19: S284-S286 (2004). *

• Bolander FF. Vitamins: not just for enzymes. Curr. Opin. Investig. Drugs 7: 912-915 (2006).

• Bonewald LF. Osteocyte biology: its implications for osteoporosis. J. Musculoskelet. Neuronal Interact. 4: 101-104 (2004).

• Boomsma MM, Stegeman CA, Kramer AB, Karsijns M, Piers DA, Tervaert JW. Prevalence of reduced bone mineral density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and the role of immunosuppressive therapy: a cross-sectional study. Osteoporos. Int. 13: 74-82 (2002). *

• Boone RH, Cheung AM, Girlan LM, Heathcote EJ. Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. Dig. Dis. Sci. 51: 1103-1112 (2006). *

• Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J. Rheumatol. Suppl. 78: 4-11 (2006). *

• Borman P, Babaoglu S, Gur G, Bingol S, Bodur H. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin. Rheumatol. 27: 443-447 (2008). *

• Boubaker J, Feki M, Hsairi M, Fekih M, Kaabachi N, Filali A, Mebazaa A. Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients. Gastroenterol. Clin. Biol. 27: 901-907 (2003).

• Boulton-Jones JR, Fenn RM, West J, Logan RF, Ryder SD. Fracture risk of women with primary biliary cirrhosis: no increase compared with general population controls. Aliment. Pharmacol. Ther. 20: 551-557 (2004). *

• Bourges O, Dorgeret S, Alberti C, Hugot JP, Sebag G, Cezard JP. Low bone mineral density in children with Crohn's disease. Arch. Pediatr. 11: 800-806 (2004).

• Bowden SA, Robinson RF, Carr R, Mahan JD. Prevalence of vitamin D deficiency and insufficiency in children with osteopenia or osteoporosis referred to a pediatric metabolic bone clinic. Pediatrics 121: e1585-e1590 (2008). *

• Bregenzer N, Schaffler A, Gelbmann CM, Steinkamp M, Reinshagen M, Scholmerich J, Andus T. Lack of correlation between the vitamin D receptor Fokl start codon polymorphism and bone mineral density in patients with Crohn's disease. Exp. Clin. Endocrinol. Diabetes 114: 1-5 (2006).

• Brodowska A, Starczewski A, Brodowski J, Szydlowska I, Nawrocka-Rutkowska J. The bone mass density in postmenopausal women using hormonal replacement therapy in relation to polymorphism in vitamin D receptor and estrogen receptor genes. Gynecol. Endocrinol. 25: 315-323 (2009).

• Brown MA, Duncan EL. Genetic studies of osteoporosis. Expert Rev. Mol. Med. 1: 1-18 (1999). *

• Brucato A, Maestroni S, Cumetti D, Thiella G, Alari G, Brambilla G, Imazio M, Doria A, Palmieri G, Adler Y. Recurrent pericarditis: infectious or autoimmune? Autoimmun. Rev. 8: 44-47 (2008).

• Burke A, Lichtenstein GR, Rombeau JL. Nutrition and ulcerative colitis. Baillieres Clin. Gastroenterol. 11: 153-174 (1997).

• Bustamante M, Nogues X, Agueda L, Jurado S, Wesselius A, Caceres E, Carreras R, Ciria M, Mellibovsky L, Balcells S, Diez-Perez A, Grinberg D. Promoter 2 -1025 T/C polymorphism in the RUNX2 gene is associated with femoral neck BMD in Spanish postmenopausal women. Calcif. Tissue Int. 81: 327-332 (2007). *

• Bustamante M, Nogues X, Mellibovsky L, Agueda L, Jurado S, Caceres E, Blanch J, Carreras R, Diez-Perez A, Grinberg D, Balcells S. Polymorphisms in the interleukin-6 receptor gene are associated with bone mineral density and body mass index in Spanish postmenopausal women. Eur. J. Endocrinol. 157: 677-684 (2007). *

• Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S, Manuokian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ, Senaldi G. CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 54: 78-86 (2005). *

• Caballero-Uribe CV, Acosta-Velez JG, Hernandez-Ruiz EA, Andrade Rodado FM, Penuela-Epalza M. Prevention, diagnosis, and treatment of glucocorticoid induced osteoporosis by rheumatologists in a Latin-American city. J. Clin. Rheumatol. 14: 153-155 (2008).

• Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: a global perspective of current status. J. Nutr. 135: 310-316 (2005). *

• Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, Biffi A, Zuin M, Podda M. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 20: 633-637 (1994).

• Cammelli D. Extra-articular manifestations of seronegative spondyloarthritis. Recenti Prog. Med. 97: 280-289 (2006).

• Campbell MS, Lichtenstein GR, Rhim AD, Faust TW. Osteopenia and osteoporosis in patients with primary sclerosing cholangitis cannot be predicted by severity of liver disease. Gastroenterology 126: A715-A716 (2004).

• Campbell MS, Lichtenstein GR, Rhim AD, Pazianas M, Faust T. Severity of liver disease does not predict osteopenia or low bone mineral density in primary sclerosing cholangitis. Liver Int. 25: 311-316 (2005). *

• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357: 905-916 (2007). *

• Cankurtaran M, Ulger Z, Dogan S, Balam Yavuz B, Halil M, Gullu I, Gedikoglu G, Aniogul S. Complications due to late diagnosis of celiac disease with co-existing plasma cell dyscrasia in an elderly patient. Aging Clin. Exp. Res. 18: 75-77 (2006).

• Capriles VD, Martini LA, Areas JA. Metabolic osteopathy in celiac disease: importance of a gluten-free diet. Nutr. Rev. 67: 599-606 (2009). *

• Carlberg C, Dunlop TW. An integrated biological approach to nuclear receptor signaling in physiological control and disease. Crit. Rev. Eukaryot. Gene Expr. 16: 1-22 (2006).

• Carlberg C, Molnar F. Detailed molecular understanding of agonistic and antagonistic vitamin D receptor ligands. Curr. Top. Med. Chem. 6: 1243-1253 (2006).

• Cashman KD. Altered bone metabolism in inflammatory disease: role for nutrition. Proc. Nutr. Soc. 67: 196-205 (2008). *

• Cashman KD. Homocysteine and osteoporotic fracture risk: a potential role for B vitamins. Nutr. Rev. 63: 29-36 (2005).

• Cashman KD. Vitamin D in childhood and adolescence. Postgrad. Med. J. 83: 230-235 (2007). *

• Cashman KD. Calcium intake, calcium bioavailability and bone health. Br. J. Nutr. 87 Suppl. 2: S169-S177 (2002).

• Castellani C, Malerba G, Sangalli A, Delmarco A, Petrelli E, Rossini M, Assael BM, Mottes M. The genetic background of osteoporosis in cystic fibrosis: association analysis with polymorphic markers in four candidate genes. J. Cyst. Fibros. 5: 229-235 (2006).

• Cauley JA. Osteoporosis in men: prevalence and investigation. Clin. Cornerstone 8 Suppl. 3: S20-S25 (2006).

• Cemlyn-Jones J, Gamboa F, Baganha M. Evaluation of bone mineral density in cystic fibrosis. Rev. Port. Pneumol. 13: S33 (2007).

• Cemlyn-Jones J, Gamboa F, Loureiro M, Fontes Baganha M. Evaluation of bone mineral density in cystic fibrosis patients. Rev. Port. Pneumol. 14: 625-634 (2008).

• Ch'ng CL, Jones MK, Kingham JG. Celiac disease and autoimmune thyroid disease. Clin. Med. Res. 5: 184-192 (2007). *

• Cha SH, Lee WK, Kwak JO, Hwang JS, Suh CK. Identification and characterization of single nucleotide polymorphisms of SLC22A11 (hOAT4) in Korean women osteoporosis patients. Mol. Cells 25: 265-271 (2008).

• Chandris P, Giannouli CC, Panayotou G, Kletsas D. Compromise in mRNA processing machinery in senescent human fibroblasts: implications for a novel potential role of Phospho-ATR (ser428). Biogerontology Jan 19 [Epub ahead of print] (2010).

• Chang J, Wang Z, Tang E, Fan Z, McCauley L, Franceschi R, Guan K, Krebsbach PH, Wang CY. Inhibition of osteoblastic bone formation by nuclear factor-kappaB. Nat. Med. 15: 682-689 (2009). *

• Chawla PS, Kochar MS. What's new in clinical pharmacology and therapeutics. WMJ 105: 24-29 (2006).

• Chen CS, Cumbler EU, Triebling AT. Coagulopathy due to celiac disease presenting as intramuscular hemorrhage. J. Gen. Intern. Med. 22: 1608-1612 (2007). *

• Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science 296: 1634-1635 (2002). *

• Chen WD, Gluud C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 3: CD004036 (2004). *

• Cheskis BJ, Freedman LP, Nagpal S. Vitamin D receptor ligands for osteoporosis. Curr. Opin. Investig. Drugs 7: 906-911 (2006).

• Cheung AM. Post-liver transplantation osteoporosis. J. Hepatol. 34: 337-338 (2001). *

• Cheung WI, Tse ML, Ngan T, Lin J, Lee WK, Poon WT, Mak TW, Leung VK, Chau TN. Liver injury associated with the use of Fructus psoraleae (Bol-gol-zhee or Bu-gu-zhi) and its related proprietary medicine. Clin. Toxicol. (Phila.) 47: 683-685 (2009).

• Chmurova N, Svecova D. Pemphigus vulgaris: a 11-year review. Bratisl. Lek. Listy. 110: 500-503 (2009).

• Chrousos GP, Kino T. Glucocorticoid signaling in the cell. Ann. N. Y. Acad. Sci. 1179: 153-166 (2009). *

• Cijevschi C, Mihai C, Zbranca E, Gogalniceanu P. Osteoporosis in liver cirrhosis. Rom. J. Gastroenterol. 14: 337-341 (2005). *

• Cohen Jr MM. The new bone biology: pathologic, molecular, and clinical correlates. Am. J. Med. Genet. A. 140: 2646-2706 (2006).

• Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).

• Cole TJ. Glucocorticoid action and the development of selective glucocorticoid receptor ligands. Biotechnol. Annu. Rev. 12: 269-300 (2006).

• Colin EM, Asmawidjaja PS, van Hamburg JP, Mus AM, van Driel M, Hazes JM, van Leeuwen JP, Lubberts E. 1,25-Dihydroxyvitamin D(3) modulates Th17 polarization and interleukin-22 expression by memory T cells from patients with early rheumatoid arthritis. Arthritis Rheum. 62: 132-142 (2009). *

• Colle I, Van Vlierberghe H. Diagnosis and therapeutic problems of primary sclerosing cholangitis. Acta Gastroenterol. Belg. 66: 155-159 (2003).

• Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 50 Suppl. 1: i1-i9 (2002). *

• Collin P. Should adults be screened for celiac disease? What are the benefits and harms of screening? Gastroenterology 128: S104-S108 (2005). *

• Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum. 56: 1966-1973 (2007). *

• Compston J. Treatments for osteoporosis - looking beyond the HORIZON. N. Engl. J. Med. 356: 1878-1880 (2007). *

• Compston JE. Detection of osteoporosis in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 9: 931-933 (1997).

• Compston JE. Can biochemical markers be used to screen patients with inflammatory bowel disease for osteoporosis? Eur. J. Gastroenterol. Hepatol. 14: 587-589 (2002).

• Conwell LS, Chang AB. Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst. Rev. 4: CD002010 (2009).

• Coronel-Perez IM, Rodríguez-Rey EM, Perez-Bernal AM, Camacho FM. Epidemiology of pemphigus in Hospital Universitario Virgen Macarena, Seville, Spain, 2005-2006. Actas Dermosifiliogr. 100: 121-125 (2009).

• Costa N, Paramanathan S, Donald DM, Wierzbicki AS, Hampson G. Factors regulating circulating vascular endothelial growth factor (VEGF): association with bone mineral density (BMD) in post-menopausal osteoporosis. Cytokine 46: 376-381 (2009).

• Cranney A, Zarkadas M, Graham ID, Butzner JD, Rashid M, Warren R, Molloy M, Case S, Burrows V, Switzer C. The Canadian celiac health survey. Dig. Dis. Sci. 52: 1087-1095 (2007). *

• Crawford BA, Labio ED, Strasser SI, McCaughan GW. Vitamin D replacement for cirrhosis-related bone disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 689-699 (2006). *

• Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am. J. Gastroenterol. 89: 47-50 (1994).

• Cucino C, Sonnenberg A. The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn's disease. Am. J. Gastroenterol. 96: 2107-2112 (2001). *

• Curran DR, McArdle JR, Talwalkar JS. Diabetes mellitus and bone disease in cystic fibrosis. Semin. Respir. Crit. Care Med. 30: 514-530 (2009).

• Cusack S, Molgaard C, Michaelsen KF, Jakobsen J, Lamberg-Allardt CJ, Cashman KD. Vitamin D and estrogen receptor-alpha genotype and indices of bone mass and bone turnover in Danish girls. J. Bone Miner. Metab. 24: 329-336 (2006). *

• Cuthbert JA, Pak CY, Zerwekh JE, Glass KD, Combes B. Bone disease in primary biliary cirrhosis: increased bone resorption and turnover in the absence of osteoporosis or osteomalacia. Hepatology 4: 1-8 (1984).

• Czerny B, Kaminski A, Kurzawski M, Kotrych D, Safranow K, Dziedziejko V, Bohatyrewicz A, Pawlik A. The association of IL-1beta, IL-2, and IL-6 gene polymorphisms with bone mineral density and osteoporosis in postmenopausal women. Eur. J. Obstet. Gynecol. Reprod. Biol. Jan 6 [Epub ahead of print] (2010).

• Daikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann. Allergy Asthma Immunol. 90: 23-27 (2003).

• Dale DC, Bolyard AA, Schwinzer BG, Pracht G, Bonilla MA, Boxer L, Freedman MH, Donadieu J, Kannourakis G, Alter BP, Cham BP, Winkelstein J, Kinsey SE, Zeidler C, Welte K. The Severe Chronic Neutropenia International Registry: 10-year follow-up report. Support Cancer Ther. 3: 220-231 (2006).

• Dang ZC, Lowik C. Dose-dependent effects of phytoestrogens on bone. Trends Endocrinol. Metab. 16: 207-213 (2005). *

• Daoussis D, Andonopoulos AP, Liossis SN. Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG Axis. Semin. Arthritis Rheum. Dec 16 [Epub ahead of print] (2008). *

• David JP, Schett G. TNF and bone. Curr. Dir. Autoimmun. 11: 135-144 (2010).

• de Azevedo MN, Nunes JV, Pasqualette HA, Tuma Mde F, Nunes LC. Bone mineral density at 45 years of age, before menopause. J. Natl. Med. Assoc. 101: 788-792 (2009).

• de Silva AP, Karunanayake AL, Dissanayaka TG, Dassanayake AS, Duminda HK, Pathmeswaran A, Wickramasinghe AR, de Silva HJ. Osteoporosis in adult Sri Lankan inflammatory bowel disease patients. World J. Gastroenterol. 15: 3528-3531 (2009). *

• Dear KL, Compston JE, Hunter JO. Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clin. Nutr. 20: 541-546 (2001).

• Decensi A, Costa A. Recent advances in cancer chemoprevention, with emphasis on breast and colorectal cancer. Eur. J. Cancer 36: 694-709 (2000). *

• Dejaco C, Haas T, Kirchgatterer A, Miehsler W, Wenzl H, Knoflach P, Petritsch W, Vogelsang H, Reinisch W, Tilg H. Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases - consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH. Z. Gastroenterol. 44: 525-538 (2006).

• Delany AM, McMahon DJ, Powell JS, Greenberg DA, Kurland ES. Osteonectin/SPARC polymorphisms in Caucasian men with idiopathic osteoporosis. Osteoporos. Int. 19: 969-978 (2008).

• Demerjian-Somogyi N, Palazzo E, Cohen-Solal M. Osteoporosis in patients with inflammatory bowel disease. Joint Bone Spine 72: 354-356 (2005). *

• Deroo BJ, Korach KS. Estrogen receptors and human disease. J. Clin. Invest. 116: 561-570 (2006). *

• Dewar DH, Ciclitira PJ. Clinical features and diagnosis of celiac disease. Gastroenterology 128: S19-S24 (2005). *

• Dickey W, Kearney N. Overweight in celiac disease: prevalence, clinical characteristics, and effect of a gluten-free diet. Am. J. Gastroenterol. 101: 2356-2359 (2006). *

• Dickey W, McMillan SA, Callender ME. High prevalence of celiac sprue among patients with primary biliary cirrhosis. J. Clin. Gastroenterol. 25: 328-329 (1997).

• Dif F, Marty C, Baudoin C, De Vernejoul MC, Levi G. Severe osteopenia in CFTR-null mice. Bone 35: 595-603 (2004).

• Dominguez-Gerpe L, Araujo-Vilar D. Prematurely aged children: molecular alterations leading to Hutchinson-Gilford Progeria and Werner syndromes. Curr. Aging Sci. 1: 202-212 (2008).

• Doring G, Conway SP. Osteoporosis in cystic fibrosis. J. Pediatr. (Rio J.) 84: 1-3 (2008). *

• Douroudis K, Tarassi K, Athanassiades T, Giannakopoulos F, Kominakis A, Thalassinos N, Papasteriades Ch. HLA alleles as predisposal factors for postmenopausal osteoporosis in a Greek population. Tissue Antigens 69: 592-596 (2007). *

• Dreiher J, Weitzman D, Cohen AD. Psoriasis and osteoporosis: a sex-specific association? J. Invest. Dermatol. 129: 1643-1649 (2009). *

• Dresner-Pollak R, Gabet Y, Steimatzky A, Hamdani G, Bab I, Ackerman Z, Weinreb M. Human parathyroid hormone 1-34 prevents bone loss in experimental biliary cirrhosis in rats. Gastroenterology 134: 259-267 (2008). *

• Dresner-Pollak R, Gelb N, Rachmilewitz D, Karmeli F, Weinreb M. Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. Gastroenterology 127: 792-801 (2004). *

• Dube C, Rostom A, Sy R, Cranney A, Saloojee N, Garritty C, Sampson M, Zhang L, Yazdi F, Mamaladze V, Pan I, Macneil J, Mack D, Patel D, Moher D. The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 128: S57-S67 (2005). *

• Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).

• Duerksen DR, Leslie WD. Positive celiac disease serology and reduced bone mineral density in adult women. Can. J. Gastroenterol. 24: 103-107 (2010).

• Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am. J. Gastroenterol. 99: 2178-2185 (2004). *

• Dujsikova H, Dite P, Tomandl J, Sevcikova A, Precechtelova M. Occurrence of metabolic osteopathy in patients with chronic pancreatitis. Pancreatology 8: 583-586 (2008).

• Dundar U, Solak M, Kavuncu V, Ozdemir M, Cakir T, Yildiz H, Evcik D. Evidence of association of vitamin D receptor Apa I gene polymorphism with bone mineral density in postmenopausal women with osteoporosis. Clin. Rheumatol. 28: 1187-1191 (2009). *

• Durieu I, Nove Josserand R. Cystic fibrosis in 2008. Rev. Med. Interne. 29: 901-907 (2008).

• El-Sohemy A. Nutrigenetics. Forum Nutr. 60: 25-30 (2007).

• Elsurer R, Tatar G, Simsek H, Balaban YH, Aydinli M, Sokmensuer C. Celiac disease in the Turkish population. Dig. Dis. Sci. 50: 136-142 (2005). *

• Encke J, Uhl W, Stremmel W, Sauer P. Immunosuppression and modulation in liver transplantation. Nephrol. Dial. Transplant. 19 Suppl. 4: iv22-iv25 (2004). *

• Ephgrave K. Extra-intestinal manifestations of Crohn's disease. Surg. Clin. North Am. 87: 673-680 (2007).

• Epstein S, Leroith D. Diabetes and fragility fractures - a burgeoning epidemic? Bone 43: 3-6 (2008).

• Erickson JM, Mawson AR. Possible role of endogenous retinoid (vitamin A) toxicity in the pathophysiology of primary biliary cirrhosis. J. Theor. Biol. 206: 47-54 (2000). *

• Erlebacher A, Filvaroff EH, Ye JQ, Derynck R. Osteoblastic responses to TGF-beta during bone remodeling. Mol. Biol. Cell 9: 1903-1918 (1998). *

• Eun IS, Park WW, Suh KT, Kim JI, Lee JS. Association between osteoprotegerin gene polymorphism and bone mineral density in patients with adolescent idiopathic scoliosis. Eur. Spine J. 18: 1936-1940 (2009). *

• Faienza MF, Brunetti G, Colucci S, Piacente L, Ciccarelli M, Giordani L, Del Vecchio GC, D'Amore M, Albanese L, Cavallo L, Grano M. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J. Clin. Endocrinol. Metab. 94: 2269-2276 (2009).

• Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY. Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. Int. J. Colorectal Dis. 24: 219-224 (2009). *

• Fang Y, Rivadeneira F, van Meurs JB, Pols HA, Ioannidis JP, Uitterlinden AG. Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk: a meta-analysis. Bone 39: 938-945 (2006).

• Fang Y, van Meurs JB, Arp P, van Leeuwen JP, Hofman A, Pols HA, Uitterlinden AG. Vitamin D binding protein genotype and osteoporosis. Calcif. Tissue Int. 85: 85-93 (2009). *

• Farias AQ, Goncalves LL, Cancado EL, Seguro AC, Campos SB, Abrantes-Lemos CP, Carrilho FJ. Bone disease in primary biliary cirrhosis: lack of association with distal renal tubular acidosis. J. Gastroenterol. Hepatol. 20: 147-152 (2005). *

• Farmer PK, He X, Schmitz ML, Rubin J, Nanes MS. Inhibitory effect of NF-kappaB on 1,25-dihydroxyvitamin D(3) and retinoid X receptor function. Am. J. Physiol. Endocrinol. Metab. 279: E213-E220 (2000). *

• Fasano A. Surprises from celiac disease. Sci. Am. 301: 54-61 (2009).

• Faulkner MA, Ryan-Haddad AM, Lenz TL, Degner K. Osteoporosis in long-term care residents with multiple sclerosis. Consult. Pharm. 20: 128-136 (2005).

• Fazzo L, Belli S, Minichilli F, Mitis F, Santoro M, Martina L, Pizzuti R, Comba P, Martuzzi M, Bianchi F. Cluster analysis of mortality and malformations in the provinces of Naples and Caserta (Campania Region). Ann. Ist Super Sanita 44: 99-111 (2008).

• Feldstein AC, Elmer PJ, Nichols GA, Herson M. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. Osteoporos. Int. 16: 2168-2174 (2005). *

• Felly C, Frei A, Lamy O. Osteoporosis and digestive disease. Rev. Med. Suisse. 2: 205-209 (2006).

• Fernandes G. Progress in nutritional immunology. Immunol. Res. 40: 244-261 (2008). *

• Fernandes G, Bhattacharya A, Rahman M, Zaman K, Banu J. Effects of n-3 fatty acids on autoimmunity and osteoporosis. Front. Biosci. 13: 4015-4020 (2008).

• Fernandez-Martin JL, Kurian S, Farmer P, Nanes MS. Tumor necrosis factor activates a nuclear inhibitor of vitamin D and retinoid-X receptors. Mol. Cell. Endocrinol. 141: 65-72 (1998).

• Ferrari S. Vitamin D in patients with osteoporosis: sufficient or necessary? Rev. Med. Suisse. 3: 1515-1516, 1518-1520 (2007).

• Ferrari S, Bonjour JP, Rizzoli R. The vitamin D receptor gene and calcium metabolism. Trends Endocrinol. Metab. 9: 259-265 (1998). *

• Fiore CE, Pennisi P, Ferro G, Ximenes B, Privitelli L, Mangiafico RA, Santoro F, Parisi N, Lombardo T. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. Horm. Metab. Res. 38: 417-422 (2006).

• Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin. Proc. 77: 453-468 (2002). *

• Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front. Biosci. 13: 3648-3660 (2008).

• Flood KL, Carr DB. Nutrition in the elderly. Curr. Opin. Gastroenterol. 20: 125-129 (2004).

• Floreani A. Osteoporosis is not a specific complication of primary biliary cirrhosis (PBC). Gut 50: 898 (2002). *

• Floreani A, Carderi I, Ferrara F, Rizzotto ER, Luisetto G, Camozzi V, Baldo V. A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis. Dig. Liver Dis. 39: 544-548 (2007).

• Floreani A, Mega A, Camozzi V, Baldo V, Plebani M, Burra P, Luisetto G. Is osteoporosis a peculiar association with primary biliary cirrhosis? World J. Gastroenterol. 11: 5347-5350 (2005). *

• Forbes A. Parenteral nutrition. Curr. Opin. Gastroenterol. 21: 192-196 (2005).

• Fountas L, Moutsatsou P, Kastanias I, Tamouridis N, Tzanela M, Anapliotou M, Sekeris CE. The contribution of vitamin D receptor gene polymorphisms in osteoporosis and familial osteoporosis. Osteoporos. Int. 10: 392-398 (1999). *

• Franck H; Kommission Osteologie der Deutschen Gesellschaft fur Rheumatologie, Braun J, Buttgereit F, Demary W, Hein G, Kekow J, Schett G, Kern PM. Bone densitometry in inflammatory rheumatic diseases: characteristics of the measurement site and disease-specific factors. Z. Rheumatol. 68: 845-850 (2009).

• Frediani B, Rossini M, Adami S, Bianchi G, Di Munno O, Sinigaglia L, Antonelli M, Minisola G. Study of vitamin D status of rheumatoid arthritis patients. Rationale and design of a cross-sectional study by the osteoporosis and metabolic bone diseases study group of the Italian Society of Rheumatology (SIR). Reumatismo 58: 314-318 (2006).

• Frei P, Fried M, Hungerbuhler V, Rammert C, Rousson V, Kullak-Ublick GA. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion 73: 40-46 (2006). *

• Frith J, Kerr S, Robinson L, Elliott C, Ghazala C, Wilton K, Pairman J, Jones DE, Newton JL. Primary biliary cirrhosis is associated with falls and significant fall related injury. QJM Jan 8 [Epub ahead of print] (2010).

• Funke S, Morava E, Czako M, Vida G, Ertl T, Kosztolanyi G. Influence of genetic polymorphisms on bone disease of preterm infants. Pediatr. Res. 60: 607-612 (2006). *

• Gabory A, Attig L, Junien C. Sexual dimorphism in environmental epigenetic programming. Mol. Cell. Endocrinol. 304: 8-18 (2009).

• Gaby AR. Natural approaches to epilepsy. Altern. Med. Rev. 12: 9-24 (2007). *

• Gaby AR. Nutritional approaches to prevention and treatment of gallstones. Altern. Med. Rev. 14: 258-267 (2009). *

• Gajewska J, Ambroszkiewicz J, Hozyasz KK. Biochemical markers of bone turnover in children with celiac disease on gluten-free diet. Med. Wieku. Rozwoj. IX: 675-683 (2005).

• Garcia-Planella E, Domenech E. Osteopenia and osteoporosis in inflammatory bowel disease. Gastroenterol. Hepatol. 27: 417-424 (2004).

• Gasser RW. Cholestasis and metabolic bone disease - a clinical review. Wien. Med. Wochenschr. 158: 553-557 (2008). *

• Gennari L. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs Today (Barc.) 42: 355-367 (2006).

• George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, Bhatia SJ, Shah S, Menon PS, Shah N. Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J. Gastroenterol. 15: 3516-3522 (2009). *

• Giaginis C, Giagini A, Theocharis S. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands as potential therapeutic agents to treat arthritis. Pharmacol. Res. 60: 160-169 (2009). *

• Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism. Fundam. Clin. Pharmacol. 21: 231-244 (2007). *

• Giaginis C, Tsantili-Kakoulidou A, Theocharis S. Peroxisome proliferator-activated receptor-gamma ligands as bone turnover modulators. Expert Opin. Investig. Drugs 16: 195-207 (2007).

• Gilbody J, Trevett M. Coeliac disease presenting with bilateral fibular stress fractures. Foot Ankle Surg. 15: 96-100 (2009).

• Giron RM, Sanchez Molini P, Almonacid C, Jimenez I, Rodriguez Salvanes F, Garcia Vadillo A, Quintana ML, Hurtado J, Ancochea J. A study of bone mineral density in adult patients with cystic fibrosis. Med. Clin. (Barc.) 123: 81-84 (2004).

• Gissel T, Rejnmark L, Mosekilde L, Vestergaard P. Intake of vitamin D and risk of breast cancer - a meta-analysis. J. Steroid Biochem. Mol. Biol. 111: 195-199 (2008).

• Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. J. Gastroenterol. Hepatol. 17: 938-948 (2002). *

• Goerres MS, Meijer JWR, Wahab PJ, Kerckhaert JAM, Groenen PJTA, Van Krieken JHJM, Mulder CJJ. Azathioprine and prednisone combination therapy in refractory Coeliac disease. Aliment. Pharmacol. Ther. 18: 487-494 (2003). *

• Gomez-Vaquero C, Fiter J, Enjuanes A, Nogues X, Diez-Perez A, Nolla JM. Influence of the BsmI polymorphism of the vitamin D receptor gene on rheumatoid arthritis clinical activity. J. Rheumatol. 34: 1823-1826 (2007).

• Gompel A, Piette JC. Systemic lupus erythematosus and hormone replacement therapy. Menopause Int. 13: 65-70 (2007).

• Gonzalez M, Ribalta J, Reyes H, Klinger J, Maggiolo P, Varleta P, Hernandez I, Delgado M, Donoso S. Primary biliary cirrhosis. The clinical experience in 31 patients. Rev. Med. Chil. 118: 1350-1354 (1990).

• Gonzalez-Avion XC, Mourino A, Rochel N, Moras D. Novel 1alpha,25-dihydroxyvitamin D(3) analogues with the side chain at C12. J. Med. Chem. 49: 1509-1516 (2006). *

• Gonzalez-Calvin JL, Mundi JL, Casado-Caballero FJ, Abadia AC, Martin-Ibanez JJ. Bone mineral density and serum levels of soluble tumor necrosis factors, estradiol, and osteoprotegerin in postmenopausal women with cirrhosis after Viral Hepatitis. J. Clin. Endocrinol. Metab. 94: 4844-4850 (2009).

• Goswami J, Hernandez-Santos N, Zuniga LA, Gaffen SL. A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss. Eur. J. Immunol. 39: 2831-2839 (2009). *

• Goswami R, Mishra SK, Kochupillai N. Prevalence and potential significance of vitamin D deficiency in Asian Indians. Indian J. Med. Res. 127: 229-238 (2008). *

• Graham LS, Parhami F, Tintut Y, Kitchen CM, Demer LL, Effros RB. Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss. Clin. Immunol. 133: 265-275 (2009). *

• Granado-Lorencio F, Herrero-Barbudo C, Olmedilla-Alonso B, Blanco-Navarro I, Perez-Sacristan B. Hypocarotenemia after bariatric surgery: a preliminary study. Obes. Surg. 19: 879-882 (2009).

• Grant WB. Does vitamin D reduce the risk of dementia? J. Alzheimers Dis. 17: 151-159 (2009).

• Grant WB, Strange RC, Garland CF. Sunshine is good medicine. The health benefits of ultraviolet-B induced vitamin D production. J. Cosmet. Dermatol. 2: 86-98 (2003).

• Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am. J. Gastroenterol. 83: 703-709 (1988).

• Gravholt CH. Clinical practice in Turner syndrome. Nat. Clin. Pract. Endocrinol. Metab. 1: 41-52 (2005). *

• Green PH. The many faces of celiac disease: clinical presentation of celiac disease in the adult population. Gastroenterology 128: S74-S78 (2005). *

• Greenberg L. Case management implications of celiac disease. Prof. Case Manag. 13: 211-217 (2008).

• Greenberg SA. Inflammatory myopathies: evaluation and management. Semin. Neurol. 28: 241-249 (2008).

• Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 55: 401-412 (1976).

• Greenwood MC, Rathi J, Hakim AJ, Scott DL, Doyle DV. Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis. Rheumatology (Oxford) 46: 1165-1167 (2007). *

• Grogan PM, Katz JS. Inflammatory myopathies. Curr. Treat. Options Neurol. 6: 155-161 (2004).

• Grundberg E, Lau EM, Pastinen T, Kindmark A, Nilsson O, Ljunggren O, Mellstrom D, Orwoll E, Redlund-Johnell I, Holmberg A, Gurd S, Leung PC, Kwok T, Ohlsson C, Mallmin H, Brandstrom H. Vitamin D receptor 3' haplotypes are unequally expressed in primary human bone cells and associated with increased fracture risk: the MrOS study in Sweden and Hong Kong. J. Bone Miner. Res. 22: 832-840 (2007).

• Gu JM, Xiao WJ, He JW, Zhang H, Hu WW, Hu YQ, Li M, Liu YJ, Fu WZ, Yu JB, Gao G, Yue H, Ke YH, Zhang ZL. Association between VDR and ESR1 gene polymorphisms with bone and obesity phenotypes in Chinese male nuclear families. Acta Pharmacol. Sin. 30: 1634-1642 (2009).

• Guanabens N, Cerda D, Monegal A, Pons F, Caballería L, Peris P, Pares A. Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis. Gastroenterology Feb 20 [Epub ahead of print] (2010). *

• Guanabens N, Enjuanes A, Alvarez L, Peris P, Caballeria L, Jesus Martinez de Osaba M, Cerda D, Monegal A, Pons F, Pares A. High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. J. Bone Miner. Metab. 27: 347-354 (2009). *

• Guanabens N, Pares A, Alvarez L, Martinez de Osaba MJ, Monegal A, Peris P, Ballesta AM, Rodes J. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J. Bone Miner. Res. 13: 731-738 (1998).

• Guanabens N, Pares A, del Rio L, Roca M, Gomez R, Munoz J, Rodes J. Sodium fluoride prevents bone loss in primary biliary cirrhosis. J. Hepatol. 15: 345-349 (1992).

• Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, Monegal A, Peris P, Rodes J. Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J. Hepatol. 42: 573-577 (2005). *

• Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl. 12: 1390-1402 (2006). *

• Guo R, Yamashita M, Zhang Q, Zhou Q, Chen D, Reynolds DG, Awad HA, Yanoso L, Zhao L, Schwarz EM, Zhang YE, Boyce BF, Xing L. Ubiquitin ligase Smurf1 mediates TNF-induced systemic bone loss by promoting proteasomal degradation of BMP signaling proteins. J. Biol. Chem. 283: 23084-23092 (2008). *

• Gupta S, Kuhnisch J, Mustafa A, Lhotak S, Schlachterman A, Slifker MJ, Klein-Szanto A, High KA, Austin RC, Kruger WD. Mouse models of cystathionine beta-synthase deficiency reveal significant threshold effects of hyperhomocysteinemia. FASEB J. 23: 883-893 (2009). *

• Gupta S, Singh RK, Dastidar S, Ray A. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert Opin. Ther. Targets 12: 291-299 (2008).

• Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm. Bowel Dis. 8: 87-92 (2002). *

• Hakamata W, Sato Y, Okuda H, Honzawa S, Saito N, Kishimoto S, Yamashita A, Sugiura T, Kittaka A, Kurihara M. (2S,2'R)-analogue of LG190178 is a major active isomer. Bioorg. Med. Chem. Lett. 18: 120-123 (2008).

• Hall WB, Sparks AA, Aris RM. Vitamin D deficiency in cystic fibrosis. Int. J. Endocrinol. 2010: 218691 (2010). *

• Hamai H, Keyserman F, Quittell LM, Worgall TS. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J. Lipid Res. 50: 1101-1108 (2009). *

• Hamilton C, Seidner DL. Metabolic bone disease and parenteral nutrition. Curr. Gastroenterol. Rep. 6: 335-341 (2004).

• Hanai J. BMP in the kidney : signaling, function and pathophysiological significance. Clin. Calcium 17: 704-710 (2007).

• Hanauer SB. Assessment, prevention and treatment of osteoporosis in inflammatory bowel disease patients: a bone of contention. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 199 (2005). *

• Hans ZJ. Celiac disease: its implications for orthopaedic nursing. Orthop. Nurs. 27: 291-294 (2008).

• Hansen LB, Vondracek SF. Prevention and treatment of nonpostmenopausal osteoporosis. Am. J. Health Syst. Pharm. 61: 2637-2654 (2004). *

• Harding G, Mak YT, Evans B, Cheung J, Macdonald D, Hampson G. The effects of dexamethasone and dehydroepiandrosterone (DHEA) on cytokines and receptor expression in a human osteoblastic cell line: potential steroid-sparing role for DHEA. Cytokine 36: 57-68 (2006).

• Haroon M, Bond U, Phelan M. Sinusitis: a possible link with adalimumab. Clin. Rheumatol. 27: 1189-1190 (2008).

• Harpavat M, Keljo DJ. Perspectives on osteoporosis in pediatric inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 225-232 (2003).

• Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J. Clin. Gastroenterol. 38: 218-224 (2004).

• Hartl WH, Jauch KW, Parhofer K, Rittler P; Working group for developing the guidelines for parenteral nutrition of The German Association for Nutritional Medicine. Complications and monitoring - Guidelines on Parenteral Nutrition, Chapter 11. Ger. Med. Sci. 7: Doc17 (2009).

• Hauser W, Gold J, Stein J, Caspary WF, Stallmach A. Health-related quality of life in adult coeliac disease in Germany: results of a national survey. Eur. J. Gastroenterol. Hepatol. 18: 747-754 (2006).

• Haussmann J, Sekar A. Chronic urticaria: a cutaneous manifestation of celiac disease. Can. J. Gastroenterol. 20: 291-293 (2006). *

• Hauzeur JP, Malaise M, Gangji V. Osteonecrosis in inflammatory bowel diseases: a review of the literature. Acta Gastroenterol. Belg. 72: 327-334 (2009).

• Havrda DE, Rathbun S, Scheid D. A case report of warfarin resistance due to azathioprine and review of the literature. Pharmacotherapy 21: 355-357 (2001).

• Hay JE. Osteoporosis in liver diseases and after liver transplantation. J. Hepatol. 38: 856-865 (2003). *

• Hay JE. Osteoporosis. Clin. Liver Dis. 2: 407-419, xi (1998).

• Hay JE. Bone disease in cholestatic liver disease. Gastroenterology 108: 276-283 (1995). *

• Hay JE, Lindor KD, Wiesner RH, Dickson ER, Krom RA, LaRusso NF. The metabolic bone disease of primary sclerosing cholangitis. Hepatology 14: 257-261 (1991).

• Heaney AP. PPAR-gamma in Cushing's disease. Pituitary 7: 265-269 (2004).

• Heaney RP, Armas LA, Shary JR, Bell NH, Binkley N, Hollis BW. 25-Hydroxylation of vitamin D3: relation to circulating vitamin D3 under various input conditions. Am. J. Clin. Nutr. 87: 1738-1742 (2008). *

• Heath JK, Suva LJ, Yoon K, Kiledjian M, Martin TJ, Rodan GA. Retinoic acid stimulates transcriptional activity from the alkaline phosphatase promoter in the immortalized rat calvarial cell line, RCT-1. Mol. Endocrinol. 6: 636-646 (1992). *

• Heathcote EJ. Diagnosis and management of cholestatic liver disease. Clin. Gastroenterol. Hepatol. 5: 776-782 (2007). *

• Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31: 1005-1013 (2000). *

• Heathcote J. Update on primary biliary cirrhosis. Can. J. Gastroenterol. 14: 43-48 (2000). *

• Heathcote J. Treatment of primary biliary cirrhosis. J. Gastroenterol. Hepatol. 11: 605-609 (1996).

• Hela S, Nihel M, Faten L, Monia F, Jalel B, Azza F, Slaheddine S. Osteoporosis and Crohn's disease. Joint Bone Spine 72: 403-407 (2005). *

• Herlong HF, Recker RR, Maddrey WC. Bone disease in primary biliary cirrhosis: histologic features and response to 25-hydroxyvitamin D. Gastroenterology 83: 103-108 (1982).

• Hernandez L, Green PH. Extraintestinal manifestationsof celiac disease. Curr. Gastroenterol. Rep. 8: 383-389 (2006).

• Herrmann M, Wildemann B, Wagner A, Wolny M, Schorr H, Taban-Shomal O, Umanskaya N, Ross S, Garcia P, Hubner U, Herrmann W. Experimental folate and vitamin B12 deficiency does not alter bone quality in rats. J. Bone Miner. Res. 24: 589-596 (2009). *

• Herzog D, Bishop N, Glorieux F, Seidman EG. Interpretation of bone mineral density values in pediatric Crohn's disease. Inflamm. Bowel Dis. 4: 261-267 (1998). *

• Hikiji H, Ishii S, Yokomizo T, Takato T, Shimizu T. A distinctive role of the leukotriene B4 receptor BLT1 in osteoclastic activity during bone loss. Proc. Natl. Acad. Sci. U.S.A. 106: 21294-21299 (2009). *

• Hill ID, Dirks MH, Liptak GS, Colletti RB, Fasano A, Guandalini S, Hoffenberg EJ, Horvath K, Murray JA, Pivor M, Seidman EG. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 40: 1-19 (2005). *

• Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Gedrich K, Kloiber S, Lucae S, Ising M, Uhr M, Holsboer F, Pollmacher T. Depression, comorbidities and the TNF-alpha system. Eur. Psychiatry 23: 421-429 (2008).

• Hind K, Truscott JG, Conway SP. Exercise during childhood and adolescence: a prophylaxis against cystic fibrosis-related low bone mineral density? Exercise for bone health in children with cystic fibrosis. J. Cyst. Fibros. 7: 270-276 (2008).

• Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL. Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone 14: 819-827 (1993).

• Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. Ann. Rheum. Dis. 68: 1171-1176 (2009). *

• Hoffmann JC, Zeitz M. Treatment of Crohn's disease. Hepatogastroenterology 47: 90-100 (2000).

• Holick MF. Vitamin D: a millenium perspective. J. Cell Biochem. 88: 296-307 (2003). *

• Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 80: 1678S-1688S (2004). *

• Holick MF. Vitamin D: important for prevention of osteoporosis, cardiovascular heart disease, type 1 diabetes, autoimmune diseases, and some cancers. South. Med. J. 98: 1024-1027 (2005).

• Holick MF. Diabetes and the vitamin D connection. Curr. Diab. Rep. 8: 393-398 (2008).

• Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin. Proc. 81: 353-373 (2006). *

• Holick MF. Sunlight, UV-radiation, vitamin D and skin cancer: how much sunlight do we need? Adv. Exp. Med. Biol. 624: 1-15 (2008). *

• Holick MF. Evolution and function of vitamin D. Recent Results Cancer Res. 164: 3-28 (2003).

• Holick MF. Vitamin D for health and in chronic kidney disease. Semin. Dial. 18: 266-275 (2005).

• Holick MF. The vitamin D epidemic and its health consequences. J. Nutr. 135: 2739S-2748S (2005). *

• Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87: 1080S-1086S (2008). *

• Holtmeier J, Leuschner U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Digestion 64: 137-150 (2001). *

• Hopman EG, von Blomberg ME, Batstra MR, Morreau H, Dekker FW, Koning F, Lamers CB, Mearin ML. Gluten tolerance in adult patients with celiac disease 20 years after diagnosis? Eur. J. Gastroenterol. Hepatol. 20: 423-429 (2008).

• Horiuchi K, Kimura T, Miyamoto T, Miyamoto K, Akiyama H, Takaishi H, Morioka H, Nakamura T, Okada Y, Blobel CP, Toyama Y. Conditional inactivation of TACE by a Sox9 promoter leads to osteoporosis and increased granulopoiesis via dysregulation of IL-17 and G-CSF. J. Immunol. 182: 2093-2101 (2009).

• Horst-Sikorska W, Ignaszak-Szczepaniak M, Marcinkowska M, Kaczmarek M, Stajgis M, Slomski R. Association analysis of vitamin D receptor gene polymorphisms with bone mineral density in young women with Graves' disease. Acta Biochim. Pol. 55: 371-380 (2008). *

• Horst-Sikorska W, Wawrzyniak A, Celczynska-Bajew L, Marcinkowska M, Dabrowski S, Kalak R, Slomski R. Polymorphism of VDR gene - the most effective molecular marker of osteoporotic bone fractures risk within postmenopausal women from Wielkopolska region of Poland. Endokrynol. Pol. 56: 233-239 (2005).

• Horwood N. Lymphocyte-derived cytokines in inflammatory arthritis. Autoimmunity 41: 230-238 (2008).

• Hourai S, Rodrigues LC, Antony P, Reina-San-Martin B, Ciesielski F, Magnier BC, Schoonjans K, Mourino A, Rochel N, Moras D. Structure-based design of a superagonist ligand for the vitamin D nuclear receptor. Chem. Biol. 15: 383-392 (2008). *

• Hoyt R. Celiac disease and osteoporosis. Arch. Intern. Med. 165: 1922 (2005). *

• Huang J, Zhao L, Xing L, Chen D. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells Dec 28 [Epub ahead of print] (2009). *

• Huang QY, Li GH, Cheung WM, Song YQ, Kung AW. Prediction of osteoporosis candidate genes by computational disease-gene identification strategy. J. Hum. Genet. 53: 644-655 (2008). *

• Huang QY, Li GH, Kung AW. The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone 45: 289-294 (2009). *

• Huang QY, Shen H, Deng HY, Conway T, Elze L, Davies KM, Recker RR, Deng HW. CA repeat polymorphism of the TNFR2 gene is not associated with bone mineral density in two independent Caucasian populations. J. Bone Miner. Metab. 24: 132-137 (2006). *

• Hubacek AJ, Weichetova M, Bohuslavova R, Skodova Jan Z, Adamkova V. Genetic polymorphisms of TGF-beta, PAI-1, and COL1A-1, and determination of bone mineral density in Caucasian females. Endocr. Regul. 40: 77-81 (2006). *

• Hubacek JA, Weichetova M, Bohuslavova R, Skodova Z, Stepan JJ, Adamkova V. No associations between genetic polymorphisms of TGFss, PAI-1, and COL1A1, and bone mineral density in Caucasian females. Endocr. Regul. 40: 107-112 (2006). *

• Hussaini SH, Oldroyd B, Stewart SP, Roman F, Smith MA, Pollard S, Lodge P, O'Grady JG, Losowsky MS. Regional bone mineral density after orthotopic liver transplantation. Eur. J. Gastroenterol. Hepatol. 11: 157-163 (1999).

• Husted LB, Harslof T, Gonzalez-Bofill N, Schmitz A, Carstens M, Stenkjaer L, Langdahl BL. Haplotypes of promoter and intron 1 polymorphisms in the COLIA1 gene are associated with increased risk of osteoporosis. Calcif. Tissue Int. 84: 85-96 (2009).

• Hwang JY, Kim SY, Lee SH, Kim GS, Go MJ, Kim SE, Kim HC, Shin HD, Park BL, Kim TH, Hong JM, Park EK, Kim HL, Lee JY, Koh JM. Association of TWIST1 gene polymorphisms with bone mineral density in postmenopausal women. Osteoporos. Int. Jul 14 [Epub ahead of print] (2009). *

• Iba K, Takada J, Yamashita T. Prospects of treatment using interferon for bone diseases. Nippon Rinsho 64: 1275-1280 (2006).

• Ichikawa T, Horie-Inoue K, Ikeda K, Blumberg B, Inoue S. Steroid and xenobiotic receptor SXR mediates vitamin K2-activated transcription of extracellular matrix-related genes and collagen accumulation in osteoblastic cells. J. Biol. Chem. 281: 16927-16934 (2006). *

• Ichikawa T, Inoue S. Molecular mechanisms of vitamin K action in the bone homeostasis. Clin. Calcium 15: 839-844 (2005).

• Ihnatko R, Kubes M. TNF signaling: early events and phosphorylation. Gen. Physiol. Biophys. 26: 159-167 (2007).

• Ikehara S. A new bone marrow transplantation method for stem cell disorders. Ann. N. Y. Acad. Sci. 1173: 774-780 (2009). *

• Ikehara S. A novel method of bone marrow transplantation (BMT) for intractable autoimmune diseases. J. Autoimmun. 30: 108-115 (2008).

• Ikehara S. Intra-bone marrow-bone marrow transplantation: a new strategy for treatment of stem cell disorders. Ann. N. Y. Acad. Sci. 1051: 626-634 (2005). *

• Inoue Y, Shimojo N, Suzuki S, Arima T, Tomiita M, Minagawa M, Kohno Y. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin. Rheumatol. 27: 909-912 (2008). *

• Isaia G, Di Stefano M, Roggia C, Ardissone P, Rosina F. Bone disorders in cholestatic liver diseases. Forum (Genova) 8: 28-38 (1998).

• Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *

• Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 13: 357-368 (2002).

• Ishii M, Egen JG, Klauschen F, Meier-Schellersheim M, Saeki Y, Vacher J, Proia RL, Germain RN. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature 458: 524-528 (2009). *

• Ishino H, Kawahito Y, Tsubouchi Y, Kohno M, Wada M, Yamamoto A, Hamaguchi M, Kadoya M, Tokunaga D, Hojo T, Matsuyama M, Yoshimura R, Yoshikawa T. Feedback control of the arachidonate cascade in osteoblastic cells by 15-deoxy-delta-prostaglandin J(2). J. Clin. Biochem. Nutr. 42: 64-69 (2008). *

• Issenman RM. Bone mineral metabolism in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 5: 192-199 (1999).

• Ito K, Inuo-Nakayama M, Matsumoto M, Kubokawa M, Sadamoto Y, Kubo H, Tanaka M, Harada N, Torigoshi K, Hirakawa M, Nawata H. Steroid-induced osteonecrosis in refractory ulcerative colitis. Fukuoka Igaku Zasshi 96: 5-10 (2005).

• Ivanisevic M, Vujovic S, Drezgic M. Effects of estro-progestagens on lipid and hormonal profiles in women with premature primary ovarian failure. Med. Pregl. 58: 296-300 (2005).

• Ivanova J, Doukova P, Boyanov M, Popivanov P. FokI and BsmI polymorphisms of the vitamin D receptor gene and bone mineral density in a random Bulgarian population sample. Endocrine 29: 413-418 (2006).

• Jackman SV, Kibel AS, Ovuworie CA, Moore RG, Kavoussi LR, Jarrett TW. Familial calcium stone disease: TaqI polymorphism and the vitamin D receptor. J. Endourol. 13: 313-316 (1999).

• Jahnsen J, Falch JA, Mowinckel P, Aadland E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 37: 192-199 (2002). *

• Jahnsen J, Falch JA, Mowinckel P, Aadland E. Bone mineral density in patients with inflammatory bowel disease: a population-based prospective two-year follow-up study. Scand. J. Gastroenterol. 39: 145-153 (2004). *

• Jakob F. Metabolic bone diseases. Internist (Berl.) 48: 1101-1117 (2007).

• Jethva R, Otsuru S, Dominici M, Horwitz EM. Cell therapy for disorders of bone. Cytotherapy 11: 3-17 (2009).

• Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl. Recept. Signal. 7: e003 (2009). *

• Jin H, Van't Hof RJ, Albagha OM, Ralston SH. Promoter and intron 1 polymorphisms of COL1A1 interact to regulate transcription and susceptibility to osteoporosis. Hum. Mol. Genet. 18: 2729-2738 (2009).

• Jin W, Chang M, Paul EM, Babu G, Lee AJ, Reiley W, Wright A, Zhang M, You J, Sun SC. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J. Clin. Invest. 118: 1858-1866 (2008). *

• Johnson MA, Davey A, Park S, Hausman DB, Poon LW. Age, race and season predict vitamin D status in African American and white octogenarians and centenarians. J. Nutr. Health Aging 12: 690-695 (2008).

• Jones S, D'Souza C, Haboubi N. Patterns and presentations of adult coeliac disease in a rural setting. Nutr. J. 5: 24 (2006). *

• Jose FA, Garnett EA, Vittinghoff E, Ferry GD, Winter HS, Baldassano RN, Kirschner BS, Cohen SA, Gold BD, Abramson O, Heyman MB. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15: 63-68 (2009). *

• Juji T, Tanaka S. RANKL vaccination. Nippon Rinsho 63: 1666-1670 (2005).

• Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr. J. 53: 27-34 (2006). *

• Kallen KJ. The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases. Biochim. Biophys. Acta 1592: 323-343 (2002). *

• Kallen KJ, Galle PR, Rose-John S. New developments in IL-6 dependent biology and therapy: where do we stand and what are the options? Expert Opin. Investig. Drugs 8: 1327-1349 (1999).

• Kamata N, Oshitani N, Sogawa M, Yamagami H, Watanabe K, Fujiwara Y, Arakawa T. Usefulness of magnetic resonance imaging for detection of asymptomatic osteonecrosis of the femoral head in patients with inflammatory bowel disease on long-term corticosteroid treatment. Scand. J. Gastroenterol. 43: 308-313 (2008). *

• Kane S, Reddy D. Guidelines do help change behavior in the management of osteoporosis by gastroenterologists. Am. J. Gastroenterol. 101: 1841-1844 (2006). *

• Kaneki M. Genomic approaches to bone and joint diseases. New insights into molecular mechanisms underlying protective effects of vitamin K on bone health. Clin. Calcium 18: 224-232 (2008).

• Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol. Nutr. Food Res. 52: 867-874 (2008). *

• Karakan T, Ozyemisci-Taskiran O, Gunendi Z, Atalay F, Tuncer C. Prevalence of IgA-antiendomysial antibody in a patient cohort with idiopathic low bone mineral density. World J. Gastroenterol. 13: 2978-2982 (2007). *

• Kastelan D, Kastelan M, Massari LP, Korsic M. Possible association of psoriasis and reduced bone mineral density due to increased TNF-alpha and IL-6 concentrations. Med. Hypotheses 67: 1403-1405 (2006).

• Katsikas GA, Maragou M, Rontogianni D, Gouma P, Koutsouvelis I, Kappou-Rigatou I. Secondary cutaneous nodular AA amyloidosis in a patient with primary Sjogren syndrome and celiac disease. J. Clin. Rheumatol. 14: 27-29 (2008).

• Katz S. Osteoporosis in patients with inflammatory bowel disease: risk factors, prevention, and treatment. Rev. Gastroenterol. Disord. 6: 63-71 (2006).

• Kaukinen K, Peraaho M, Lindfors K, Partanen J, Woolley N, Pikkarainen P, Karvonen AL, Laasanen T, Sievanen H, Maki M, Collin P. Persistent small bowel mucosal villous atrophy without symptoms in coeliac disease. Aliment. Pharmacol. Ther. 25: 1237-1245 (2007). *

• Kavuncu V, Dundar U, Ciftci IH, Evcik D, Yigit I. Is there any requirement for celiac disease screening routinely in postmenapausal women with osteoporosis? Rheumatol. Int. 29: 841-845 (2009). *

• Kawaguchi H. Molecular mechanism of age-related osteoporosis. Nippon Ronen Igakkai Zasshi 41: 612-615 (2004).

• Kawelke N, Bentmann A, Hackl N, Hager HD, Feick P, Geursen A, Singer MV, Nakchbandi IA. An isoform of fibronectin mediates bone loss in patients with primary biliary cirrhosis by suppressing bone formation. J. Bone Miner. Res. 23: 1278-1286 (2008). *

• Kefalides PT, Hanauer SB. Ulcerative colitis: diagnosis and management. Case study and commentary. Hospital Physician June: 53-63 (2002). *

• Khadgawat R, Makharia GK, Puri K. Evaluation of bone mineral density among patients with inflammatory bowel disease in a tertiary care setting in India. Indian J. Gastroenterol. 27: 103-106 (2008). *

• Kim H, Choi HK, Shin JH, Kim KH, Huh JY, Lee SA, Ko CY, Kim HS, Shin HI, Lee HJ, Jeong D, Kim N, Choi Y, Lee SY. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J. Clin. Invest. 119: 813-825 (2009). *

• Kim H, Chun S, Ku SY, Suh CS, Choi YM, Kim JG. Association between polymorphisms in tumor necrosis factor (TNF) and TNF receptor genes and circulating TNF, soluble TNF receptor levels, and bone mineral density in postmenopausal Korean women. Menopause 16: 1014-1020 (2009).

• Kim HJ, Zhang K, Zhang L, Ross FP, Teitelbaum SL, Faccio R. The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 106: 2325-2330 (2009). *

• Kim HR, Kim HY, Lee SH. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 45: 1197-1200 (2006). *

• Kim MH, Lee GS, Jung EM, Choi KC, Jeung EB. The negative effect of dexamethasone on calcium-processing gene expressions is associated with a glucocorticoid-induced calcium-absorbing disorder. Life Sci. 85: 146-152 (2009). *

• Kim WK, Meliton V, Tetradis S, Weinmaster G, Hahn TJ, Carlson M, Nelson SF, Parhami F. Osteogenic oxysterol, 20(S)-hydroxycholesterol, induces Notch target gene expression in bone marrow stromal cells. J. Bone Miner. Res. Oct 19 [Epub ahead of print] (2009). *

• King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs 67: 965-974 (2007).

• Kirchgatterer A, Wenzl HH, Aschl G, Hinterreiter M, Stadler B, Hinterleitner TA, Petritsch W, Knoflach P. Examination, prevention and treatment of osteoporosis in patients with inflammatory bowel disease: recommendations and reality. Acta Med. Austriaca 29: 120-123 (2002).

• Kitazaki S, Mitsuyama K, Masuda J, Harada K, Yamasaki H, Kuwaki K, Takedatsu H, Sugiyama G, Tsuruta O, Sata M. Clinical trial: comparison of alendronate and alfacalcidol in glucocorticoid-associated osteoporosis in patients with ulcerative colitis. Aliment. Pharmacol. Ther. 29: 424-430 (2009). *

• Kittaka A, Hara H, Takano M, Sawada D, Arai MA, Takagi K, Chida T, Harada Y, Saito H, Takenouchi K, Ishizuka S, Hayashi K, Ikushiro S, Sakaki T, Sugiura T, Chen TC. Synthesis and biological activities of 14-epi-MART-10 and 14-epi-MART-11: implications for cancer and osteoporosis treatment. Anticancer Res. 29: 3563-3569 (2009).

• Kittaka A, Saito N, Takano M. Recent progress of study on vitamin D analogs. Clin. Calcium 16: 1154-1165 (2006).

• Kizilisik AT, Grewal HP, Shokouh-Amiri MH, Vera SR, Hathaway DK, Gaber AO. Impact of long-term immunosuppressive therapy on psychosocial and physical well being in liver transplant recipients. Prog. Transplant. 13: 278-283 (2003).

• Klaus J, Reinshagen M, Adler G, Boehm B, von Tirpitz C. Bones and Crohn's: estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density. BMC Gastroenterol. 8: 48 (2008). *

• Kleerekoper M, Nelson DA. Is BMD testing appropriate for all menopausal women? Int. J. Fertil. Womens Med. 50: 61-66 (2005).

• Klein TW, Newton CA. Therapeutic potential of cannabinoid-based drugs. Adv. Exp. Med. Biol. 601: 395-413 (2007).

• Klejna K, Naumnik B, Gasowska K, Mysliwiec M. OPG/RANK/RANKL signaling system and its significance in nephrology. Folia Histochem. Cytobiol. 47: 199-206 (2009). *

• Kluge G, Borte M, Richter T, Kahn T, Borte G. Osteodensitometry in children and adolescents with inflammatory bowel disease. Rofo. 179: 58-64 (2007).

• Kmiec Z, Sokolowska I. Role of tumor necrosis factor family ligands in the pathogenesis of rheumatoid arthritis - new therapeutical opportunities. Pol. Merkur. Lekarski. 22: 300-304 (2007).

• Knudsen S, Harslof T, Husted LB, Carstens M, Stenkjaer L, Langdahl BL. The effect of interleukin-1alpha polymorphisms on bone mineral density and the risk of vertebral fractures. Calcif. Tissue Int. 80: 21-30 (2007). *

• Kocian J, Kocianova J. Bone demineralization in Crohn's disease, its diagnosis, therapy and prevention. Cas. Lek. Cesk. 138: 522-524 (1999).

• Kogure T, Ueno Y, Kimura O, Kondo Y, Inoue J, Fukushima K, Iwasaki T, Shimosegawa T. A novel third generation bisphosphonate, minodronate (YM529), prevented proliferation and migration of hepatocellular carcinoma cells through inhibition of mevalonate pathway. Hepatol. Res. 39: 479-489 (2009). *

• Kolho KL, Farkkila MA, Savilahti E. Undiagnosed coeliac disease is common in Finnish adults. Scand. J. Gastroenterol. 33: 1280-1283 (1998). *

• Kornbluth A, Hayes M, Feldman S, Hunt M, Fried-Boxt E, Lichtiger S, Legnani P, George J, Young J. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. Am. J. Gastroenterol. 101: 1546-1550 (2006). *

• Koszewski NJ, Reinhardt TA, Horst RL. Differential effects of 20-epi vitamin D analogs on the vitamin D receptor homodimer. J. Bone Miner. Res. 14: 509-517 (1999).

• Kotake S, Nanke Y, Yago T, Yamanaka H. Rheumatoid arthritis in the context of bone and cartilage. Serum markers of synovitis and bone metabolism in rheumatoid arthritis. Clin. Calcium 19: 362-371 (2009).

• Kotake S, Yago T, Nanke Y. Effects of biologic therapies on systemic osteoporosis in patients with rheumatoid arthritis. Nippon Rinsho 67: 996-1002 (2009).

• Kraus MR, Scheurlen M. Diagnosis and treatment of intrahepatic cholestasis syndrome. MMW Fortschr. Med. 146: 34-37 (2004).

• Kreck S, Klaus J, Leidl R, von Tirpitz C, Konnopka A, Matschinger H, Konig HH. Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. Pharmacoeconomics 26: 311-328 (2008).

• Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116: 1202-1209 (2006). *

• Krums LM, Parfenov AI, Kondrat'eva OA, Khomeriki SG, Kuzin AV. Dental diseases and osteoporosis may serve a diagnostic key for celiac disease (a case report). Ter. Arkh. 78: 64-66 (2006).

• Kubincova L, Payer J, Killinger Z, Macugova I, Berakova K. Celiac disease - a frequent cause of "idiopathic osteoporosis" in premenopausal and early postmenopausal women. Vnitr. Lek. 53: 1296-1302 (2007).

• Kubodera N. Progress in research on vitamin D analogs. Clin. Calcium 16: 1167-1172 (2006).

• Kubodera N. D-hormone derivatives for the treatment of osteoporosis: from alfacalcidol to eldecalcitol. Mini Rev. Med. Chem. 9: 1416-1422 (2009).

• Kuhn H, O'Donnell VB. Inflammation and immune regulation by 12/15-lipoxygenases. Prog. Lipid Res. 45: 334-356 (2006). *

• Kurppa K, Collin P, Sievanen H, Huhtala H, Maki M, Kaukinen K. Gastrointestinal symptoms, quality of life and bone mineral density in mild enteropathic coeliac disease: a prospective clinical trial. Scand. J. Gastroenterol. 45: 305-314 (2010). *

• Kusek J, Seremak-Mrozikiewicz A, Drews K, Mikolajczak P, Czerny B, Maciejewska M, Bogacz A, Derebecka-Holysz N, Barlik M, Mrozikiewicz PM. The influence of interleukin-6 and tumor necrosis factor alpha gene polymorphisms on bone mineral density in postmenopausal women. Ginekol. Pol. 79: 426-431 (2008).

• Kvien TK, Uhlig T. The population based studies in rheumatoid arthritis. A method of longterm followup studies. J. Rheumatol. Suppl. 69: 35-40 (2004).

• La Vignera S, Vicari E, Tumino S, Ciotta L, Condorelli R, Vicari LO, Calogero AE. L-Thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history. Minerva Ginecol. 60: 475-484 (2008).

• Laaksonen MM, Outila TA, Karkkainen MU, Kemi VE, Rita HJ, Perola M, Valsta LM, Lamberg-Allardt CJ. Associations of vitamin D receptor, calcium-sensing receptor and parathyroid hormone gene polymorphisms with calcium homeostasis and peripheral bone density in adult Finns. J. Nutrigenet. Nutrigenomics 2: 55-63 (2009).

• Labovitz JM, Revill K. Osteoporosis: pathogenesis, new therapies and surgical implications. Clin. Podiatr. Med. Surg. 24: 311-332 (2007).

• Lakatos LP, Bajnok E, Hegedus D, Toth T, Lakatos P, Szalay F. Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 14: 733-740 (2002).

• Lakatos PL, Bajnok E, Tornai I, Folhoffer A, Horvath A, Lakatos P, Habior A, Szalay F. Insulin-like growth factor I gene microsatellite repeat, collagen type Ialpha1 gene Sp1 polymorphism, and bone disease in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 16: 753-759 (2004).

• Lakatos PL, Bajnok E, Tornai I, Folhoffer A, Horvath A, Lakatos P, Szalay F. Decreased bone mineral density and gene polymorphism in primary biliary cirrhosis. Orv. Hetil. 145: 331-336 (2004).

• Lambert GM. Does intestinal resection affect the absorption of essential vitamins, minerals, and bile salts? An overview of the literature. Ostomy Wound Manage. 54: 36-47 (2008).

• Lamberts SW, Uitterlinden AG. Genetic testing in clinical practice. Annu. Rev. Med. 60: 431-442 (2009). *

• Lane N. Osteoporosis - is there a rational approach to fracture prevention? Bull. Hosp. Jt. Dis. 64: 67-71 (2006).

• Lane NE. Therapy insight: osteoporosis and osteonecrosis in systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2: 562-569 (2006). *

• Lang SM, Fischer R, Stratakis DF, Huber RM. High prevalence of osteoporosis in adult cystic fibrosis patients. Dtsch. Med. Wochenschr. 129: 1551-1555 (2004).

• Langdahl BL, Carstens M, Stenkjaer L, Eriksen EF. Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis. Bone 32: 297-310 (2003). *

• Langdahl BL, Lokke E, Carstens M, Stenkjaer LL, Eriksen EF. Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1 receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. J. Bone Miner. Res. 15: 402-414 (2000).

• Lange U, Teichmann J, Muller-Ladner U, Strunk J. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) 44: 1546-1548 (2005). *

• Lange U, Teichmann J, Obermayer-Pietsch B. Genetic aspects of osteopenia/osteoporosis in ankylosing spondylitis. Z. Orthop. Unfall. 147: 577-581 (2009).

• Langrock T, Czihal P, Hoffmann R. Amino acid analysis by hydrophilic interaction chromatography coupled on-line to electrospray ionization mass spectrometry. Amino Acids 30: 291-297 (2006). *

• Lapcevic M. Autoimmune thyroid disease and associated diseases. Srp. Arh. Celok. Lek. 133 Suppl. 1: 84-87 (2005).

• Lashner BA. Clinical advances in ulcerative colitis. American College of Gastroenterology 68th Annual Scientific Meeting and Postgraduate Course, October 10 - 15, 2003, Baltimore, Maryland (2003).

• Lasker JN, Sogolow ED, Sharim RR. The role of an online community for people with a rare disease: content analysis of messages posted on a primary biliary cirrhosis mailinglist. J. Med. Internet Res. 7: e10 (2005). *

• Lau HH, Ng MY, Cheung WM, Paterson AD, Sham PC, Luk KD, Chan V, Kung AW. Assessment of linkage and association of 13 genetic loci with bone mineral density. J. Bone Miner. Metab. 24: 226-234 (2006). *

• Lavigne P, Benderdour M, Lajeunesse D, Shi Q, Fernandes JC. Expression of ICAM-1 by osteoblasts in healthy individuals and in patients suffering from osteoarthritis and osteoporosis. Bone 35: 463-470 (2004).

• Lazebnik LB, Parfenov AI. Crohn’s disease of small intestine: versions of clinical picture and problems of differential diagnosis. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 43-44 (2006). *

• Le Gars L, Grandpierre C, Chazouilleres O, Berenbaum F, Poupon R. Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease. Joint Bone Spine 69: 195-200 (2002).

• Lee HJ, Koh JM, Hwang JY, Choi KY, Lee SH, Park EK, Kim TH, Han BG, Kim GS, Kim SY, Lee JY. Association of a RUNX2 promoter polymorphism with bone mineral density in postmenopausal Korean women. Calcif. Tissue Int. 84: 439-445 (2009). *

• Lee KM. Nutrition in inflammatory bowel disease. Korean J. Gastroenterol. 52: 1-8 (2008).

• Lee N, Radford-Smith G, Taaffe DR. Bone loss in Crohn's disease: exercise as a potential countermeasure. Inflamm. Bowel Dis. 11: 1108-1118 (2005). *

• Lee SJ, Lee DH, Yoo HW, Koo SK, Park ES, Park JW, Lim HG, Jung SC. Identification and functional analysis of cystathionine beta-synthase gene mutations in patients with homocystinuria. J. Hum. Genet. 50: 648-654 (2005). *

• Legroux-Gerot I, Leloire O, Blanckaert F, Tonnel F, Grardel B, Ducrocq JL, Cortet B. Screening for celiac disease in patients with osteoporosis. Joint Bone Spine 76: 162-165 (2009). *

• Leitzmann C. Vegetarian diets: what are the advantages? Forum Nutr. 57: 147-156 (2005).

• Lekva T, Bollerslev J, Kristo C, Olstad OK, Ueland T, Jemtland R. The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing's syndrome and may play a role in glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. Oct 29 [Epub ahead of print] (2009).

• Lerner UH. New molecules in the tumor necrosus factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. Crit. Rev. Oral Biol. Med. 15: 64-81 (2004). *

• Leslie WD, Bernstein CN, Leboff MS; American Gastroenterological Association Clinical Practice Commitee. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 125: 941-966 (2003). *

• Leuschner M, Guldutuna S, You T, Hubner K, Bhatti S, Leuschner U. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J. Hepatol. 25: 49-57 (1996). *

• Leuschner U. Cholestatic hepatopathy: primary biliary cirrhosis. Schweiz. Rundsch. Med. Prax. 89: 1043-1048 (2000).

• Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37 (2003). *

• Levy C, Lindor KD. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin. Liver Dis. 7: 901-910 (2003).

• Levy C, Lindor KD. Treatment options for primary biliary cirrhosis and primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 6: 93-103 (2003).

• Levy C, Lindor KD. Management of primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 6: 493-498 (2003).

• Li H, Liu Y, Zhang Q, Jing Y, Chen S, Song Z, Yan J, Li Y, Wu X, Zhang X, Zhang Y, Case J, Yu M, Ingram DA, Yang FC. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Pediatr. Res. 65: 613-618 (2009). *

• Li WF, Hou SX, Yu B, Li MM, Ferec C, Chen JM. Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum. Genet. Dec 12 [Epub ahead of print] (2009). *

• Licata A. Osteoporosis in men: suspect secondary disease first. Cleve. Clin. J. Med. 70: 247-254 (2003).

• Lichtenstein GR. Management of bone loss in inflammatory bowel disease. Semin. Gastrointest. Dis. 12: 275-283 (2001).

• Lichtenstein GR. Preface. Gastroenterol. Clin. North Am. 35: xiii-xiv (2006). *

• Lichtenstein GR, Sands BE, Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm. Bowel Dis. 12: 797-813 (2006). *

• Lidofsky S, Smith J. Glucocorticoid-induced osteoporosis in inflammatory bowel disease. Med. Health R. I. 92: 128-130 (2009).

• Lindor KD, Jorgensen RA, Tiegs RD, Khosla S, Dickson ER. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J. Hepatol. 33: 878-882 (2000). *

• Lips P. Vitamin D physiology. Prog. Biophys. Mol. Biol. 92: 4-8 (2006). *

• Listrom C, Holt K. Inflammatory bowel disease. Emerg. Med. 36: 24-28 (2004).

• Liu JB, Gao X, Zhang FB, Yang L, Xiao YL, Zhang RD, Li ZP, Hu PJ, Chen MH. The risk factor for low bone mineral density in patients with inflammatory bowel disease. Zhonghua Nei Ke Za Zhi 48: 833-836 (2009).

• Liu PY, Zhang YY, Lu Y, Long JR, Shen H, Zhao LJ, Xu FH, Xiao P, Xiong DH, Liu YJ, Recker RR, Deng HW. A survey of haplotype variants at several disease candidate genes: the importance of rare variants for complex diseases. J. Med. Genet. 42: 221-227 (2005). *

• Liu SZ, Yan H, Hou WK, Xu P, Tian J, Tian LF, Zhu BF, Ma J, Lu SM. Relationships between endothelial nitric oxide synthase gene polymorphisms and osteoporosis in postmenopausal women. J. Zhejiang Univ. Sci. B. 10: 609-618 (2009).

• Loftus EV. Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr. Gastroenterol. Rep. 6: 506-513 (2004).

• Loftus EV Jr, Achenbach SJ, Sandborn WJ, Tremaine WJ, Oberg AL, Melton LJ 3rd. Risk of fracture in ulcerative colitis: a population-based study from Olmsted county, Minnesota. Clin. Gastroenterol. Hepatol. 1: 465-473 (2003). *

• Loftus EV Jr, Crowson CS, Sandborn WJ, Tremaine WJ, O'Fallon WM, Melton LJ 3rd. Long-term fracture risk in patients with Crohn's disease: a population-based study in Olmsted County, Minnesota. Gastroenterology 123: 468-475 (2002). *

• Lohse AW. Other extra-hepatic and extra-intestinal diseases in primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 78. October 15-16 (2003). *

• Lohse AW. Standard treatment of autoimmune hepatitis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 65-66 (2004). *

• Long MD, Thiny MT, Sandler RS, Gangarosa LM. Bone health in a tertiary-care gastroenterology and hepatology population. Dig. Dis. Sci. Feb 2 [Epub ahead of print] (2010). *

• Long RG, Meinhard E, Skinner RK, Varghese Z, Wills MR, Sherlock S. Clinical, biochemical, and histological studies of osteomalacia, osteoporosis, and parathyroid function in chronic liver disease. Gut 19: 85-90 (1978). *

• Long RG, Varghese Z, Meinhard EA, Skinner RK, Wills MR, Sherlock S. Parenteral 1,25-dihydroxycholecalciferol in hepatic osteomalacia. Br. Med. J. 1: 75-77 (1978). *

• Lopez MJ, Lee YM. Primary sclerosing cholangitis and primary biliary cirrhosis. The American College of Gastroenterology (http://www.acg.gi.org/patients/gihealth/pdf/sclerosing.pdf) (2005). *

• Lopez San Roman A, Rivero Fernandez M. Current status of inflammatory bowel disease treatment. Rev. Clin. Esp. 207: 298-300 (2007).

• Lopez-Collazo E, Fuentes-Prior P, Arnalich F, Del Fresno C. Pathophysiology of interleukin-1 receptor-associated kinase-M: implications in refractory state. Curr. Opin. Infect. Dis. 19: 237-244 (2006).

• Lories RJ, Boonen S, Peeters J, de Vlam K, Luyten FP. Evidence for a differential association of the Arg200Trp single-nucleotide polymorphism in FRZB with hip osteoarthritis and osteoporosis. Rheumatology (Oxford) 45: 113-114 (2006). *

• Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, Tran-Van-Nhieu J, Karsak M, Zimmer A, Mallat A. CB2 receptors as new therapeutic targets for liver diseases. Br. J. Pharmacol. 153: 286-289 (2008). *

• Lovas K, Gjesdal C, Christensen M, Wolff AS, Almas B, Svartberg J, Fougner K, Syversen U, Bollerslev J, Falch J, Hunt P, Chatterjee VK, Husebye E. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur. J. Endocrinol. 160: 993-1002 (2009).

• Lowdon J. Low vitamin D status: on the increase? J. Fam. Health Care 18: 55-57 (2008).

• Lu T, Achari Y, Sciore P, Hart DA. Estrogen receptor alpha regulates matrix metalloproteinase-13 promoter activity primarily through the AP-1 transcriptional regulatory site. Biochim. Biophys. Acta 1762: 719-731 (2006). *

• Lucas RM, Ponsonby AL. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation? Prog. Biophys. Mol. Biol. 92: 140-149 (2006). *

• Lucas RM, Ponsonby AL, Pasco JA, Morley R. Future health implications of prenatal and early-life vitamin D status. Nutr. Rev. 66: 710-720 (2008). *

• Ludvigsson JF, Michaelsson K, Ekbom A, Montgomery SM. Coeliac disease and the risk of fractures - a general population-based cohort study. Aliment. Pharmacol. Ther. 25: 273-285 (2007). *

• Ma Y, Khalifa B, Yee YK, Lu J, Memezawa A, Savkur RS, Yamamoto Y, Chintalacharuvu SR, Yamaoka K, Stayrook KR, Bramlett KS, Zeng QQ, Chandrasekhar S, Yu XP, Linebarger JH, Iturria SJ, Burris TP, Kato S, Chin WW, Nagpal S. Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators. J. Clin. Invest. 116: 892-904 (2006). *

• Macdonald HM, McGuigan FE, Stewart A, Black AJ, Fraser WD, Ralston S, Reid DM. Large-scale population-based study shows no evidence of association between common polymorphism of the VDR gene and BMD in British women. J. Bone Miner. Res. 21: 151-162 (2006). *

• Maclaughlin EJ, Raehl CL, Reilly C. Celiac disease and osteoporosis. Am. J. Health Syst. Pharm. 65: 1601-1602 (2008).

• MacLean CH, Mojica WA, Morton SC, Pencharz J, Hasenfeld Garland R, Tu W, Newberry SJ, Jungvig LK, Grossman J, Khanna P, Rhodes S, Shekelle P. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. Evid. Rep. Technol. Assess. 89: 1-4 (2004). *

• Maddali Bongi S, Manetti R, Melchiorre D, Turchini S, Boccaccini P, Vanni L, Maggi E. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis anti-CCP and bone damage in RA. Autoimmunity 37: 495-501 (2004).

• Magana JJ, Gomez R, Cisneros B, Casas L, Valdes-Flores M. Association of interleukin-6 gene polymorphisms with bone mineral density in Mexican women. Arch. Med. Res. 39: 618-624 (2008).

• Maganti RM, Reveille JD, Williams FM. Therapy insight: the changing spectrum of rheumatic disease in HIV infection. Nat. Clin. Pract. Rheumatol. 4: 428-438 (2008).

• Maggi M, Crescioli C, Morelli A, Colli E, Adorini L. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J. Endocrinol. Invest. 29: 665-674 (2006).

• Maggio M, Artoni A, Lauretani F, Borghi L, Nouvenne A, Valenti G, Ceda GP. The impact of omega-3 fatty acids on osteoporosis. Curr. Pharm. Des. 15: 4157-4164 (2009).

• Malemba JJ, Mbuyi-Muamba JM. Clinical and epidemiological features of rheumatic diseases in patients attending the university hospital in Kinshasa. Clin. Rheumatol. 27: 47-54 (2008). *

• Mangione RA. Celiac disease and osteoporosis. Am. J. Health Syst. Pharm. 65: 1601 (2008).

• Mangione RA, Patel PN. Caring for patients with celiac disease: the role of the pharmacist. J. Am. Pharm. Assoc. 48: e125-e135 (2003).

• Marie PJ. The calcium sensing receptor in bone cells: a potential therapeutic target in osteoporosis. Bone Aug 3 [Epub ahead of print] (2009). *

• Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu. Rev. Med. 60: 39-54 (2009). *

• Marques-Deak A, Cizza G, Sternberg E. Brain-immune interactions and disease susceptibility. Mol. Psychiatry 10: 239-250 (2005).

• Marshall TG. Vitamin D discovery outpaces FDA decision making. Bioessays 30: 173-182 (2008). *

• Martignetti JA, Aqeel AA, Sewairi WA, Boumah CE, Kambouris M, Mayouf SA, Sheth KV, Eid WA, Dowling O, Harris J, Glucksman MJ, Bahabri S, Meyer BF, Desnick RJ. Mutation of the matrix metalloproteinase 2 gene (MMP2) causes a multicentric osteolysis and arthritis syndrome. Nat. Genet. 28: 261-265 (2001). *

• Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral Maxillofac. Surg. 65: 2397-2410 (2007).

• Massart F, Marcucci G, Brandi ML. Pharmacogenetics of bone treatments: the VDR and ERalpha gene story. Pharmacogenomics 9: 733-746 (2008).

• Mata-Granados JM, Luque de Castro MD, Quesada Gomez JM. Inappropriate serum levels of retinol, alpha-tocopherol, 25 hydroxyvitamin D(3) and 24,25 dihydroxyvitamin D(3) levels in healthy Spanish adults: simultaneous assessment by HPLC. Clin. Biochem. 41: 676-680 (2008). *

• Matloff DS, Kaplan MM, Neer RM, Goldberg MJ, Bitman W, Wolfe HJ. Osteoporosis in primary biliary cirrhosis: effects of 25-hydroxyvitamin D3 treatment. Gastroenterology 83: 97-102 (1982).

• Matsunawa M, Amano Y, Endo K, Uno S, Sakaki T, Yamada S, Makishima M. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Toxicol. Sci. 109: 50-58 (2009). *

• Matsushita H, Barrios JA, Shea JE, Miller SC. Dietary fish oil results in a greater bone mass and bone formation indices in aged ovariectomized rats. J. Bone Miner. Metab. 26: 241-247 (2008). *

• Matysiak-Budnik T, Malamut G, Patey-Mariaud de Serre N, Grosdidier E, Seguier S, Brousse N, Caillat-Zucman S, Cerf-Bensussan N, Schmitz J, Cellier C. Long-term follow-up of 61 celiac patients diagnosed in childhood: evolution toward latency is possible on a normal diet. Gut 56: 1379-1386 (2007). *

• Mauck KF, Clarke BL. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin. Proc. 81: 662-672 (2006). *

• Mauro M, Radovic V, Armstrong D. Improvement of lumbar bone mass after infliximab therapy in Crohn's disease patients. Can. J. Gastroenterol. 21: 637-642 (2007). *

• McCarthy D, Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Seasonality of vitamin D status and bone turnover in patients with Crohn's disease. Aliment. Pharmacol. Ther. 21: 1073-1083 (2005). *

• McCaughan GW, Feller RB. Osteoporosis in chronic liver disease: pathogenesis, risk factors, and management. Dig. Dis. 12: 223-231 (1994).

• McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf. 25: 913-927 (2002).

• McFarlane XA, Bhalla AK, Reeves DE, Morgan LM, Robertson DA. Osteoporosis in treated adult coeliac disease. Gut 36: 710-714 (1995). *

• McFarlin BK, Flynn MG, Campbell WW, Craig BA, Robinson JP, Stewart LK, Timmerman KL, Coen PM. Physical activity status, but not age, influences inflammatory biomarkers and Toll-like receptor 4. J. Gerontol. A. Biol. Sci. Med. Sci. 61: 388-393 (2006).

• McGough N, Cummings JH. Coeliac disease: a diverse clinical syndrome caused by intolerance of wheat, barley and rye. Proc. Nutr. Soc. 64: 434-450 (2005). *

• McLaughlin SD, Perry-Woodford ZL, Clark SK, Johnson MW, Tekkis PP, Ciclitira PJ, Nicholls RJ. Osteoporosis in patients over 50 years of age following restorative proctocolectomy for ulcerative colitis: is DXA screening warranted? Inflamm. Bowel Dis. 16: 250-255 (2010).

• McMahon MS, Ueki Y. Does anti-TNF-alpha have a role in the treatment of osteoporosis? Bull. N.Y.U. Hosp. Jt. Dis. 66: 280-281 (2008). *

• Mearin ML, Ivarsson A, Dickey W. Coeliac disease: is it time for mass screening? Best Pract. Res. Clin. Gastroenterol. 19: 441-452 (2005).

• Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 study. J. Rheumatol. Dec 23 [Epub ahead of print] (2009).

• Meek SE, Nix K. Hypocalcemia after alendronate therapy in a patient with celiac disease. Endocr. Pract. 13: 403-407 (2007).

• Meltzer E, Dolev E. Inflammatory bowel disease and osteoporosis - an evidence-based connection. Harefuah. 140: 590-593, 679 (2001).

• Menardo G, Brizzolara R, Bonassi S, Marchetti A, Dante GL, Pistone C, Marenco D, Rabellino V, Buscaglia S, Scarso R, Murialdo M, Venturino E, Marino CE, Descalzi D, Minetti F, Bagnasco M, Pesce G. Population screening for coeliac disease in a low prevalence area in Italy. Scand. J. Gastroenterol. 41: 1414-1420 (2006). *

• Mencej S, Prezelj J, Kocijancic A, Ostanek B, Marc J. Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women. Maturitas 55: 219-226 (2006).

• Menchen LM, Ripoll C, Breton I, Moreno C, de la Cuerda C, Camblor M, Garcia-Peris P, Gonzalez-Lara V, Cos E. Osteoporosis and inflammatory bowel disease. Nutr. Hosp. 20: 26-37 (2005).

• Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Escarcega RO, Jimenez-Hernandez M, Etchegaray-Morales I, Soto-Vega E, Munoz-Guarneros M, Lopez-Colombo A, Deleze-Hinojosa M, Cervera R. Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin. Rheumatol. 28: 65-70 (2009).

• Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Munoz-Guarneros M, Escarcega RO, Jimenez-Hernandez M, Munguia-Realpozo P, Sandoval-Cruz M, Deleze-Hinojosa M, Lopez-Colombo A, Cervera R. Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin. Rheumatol. 28: 579-585 (2009). *

• Menon KV, Angulo P, Boe GM, Lindor KD. Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis. Am. J. Gastroenterol. 98: 889-892 (2003). *

• Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J. Hepatol. 35: 316-323 (2001). *

• Mensah KA, Li J, Schwarz EM. The emerging field of osteoimmunology. Immunol. Res. Jan 30 [Epub ahead of print] (2009). *

• Mesmar M, Kanan RM. Possible association of combined vitamin D receptor and estrogen receptor genotypes and low bone mineral density in jordanian postmenopausal women. Genet. Test. Mol. Biomarkers 13: 603-609 (2009).

• Meys E, Fontanges E, Fourcade N, Thomasson A, Pouyet M, Delmas PD. Bone loss after orthotopic liver transplantation. Am. J. Med. 97: 445-450 (1994).

• Mezquita Raya P, Munoz Torres M, Lopez Rodriguez F, Martinez Martin N, Conde Valero A, Ortego Centeno N, Gonzalez Calvin J, Raya Alvarez E, Luna Jd Jde D, Escobar Jimenez F. Prevalence of vitamin D deficiency in populations at risk for osteoporosis: impact on bone integrity. Med. Clin. (Barc.) 119: 85-89 (2002).

• Michaels A, Levy C. The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61 (2008). *

• Miheller P, Muzes G, Hritz I, Lakatos G, Pregun I, Lakatos P, Herszenyi L, Tulassay Z. Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm. Bowel Dis. 15: 1656-1662 (2009). *

• Miheller P, Muzes G, Racz K, Blazovits A, Lakatos P, Herszenyi L, Tulassay Z. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm. Bowel Dis. 13: 1379-1384 (2007). *

• Miheller P, Muzes G, Zagoni T, Toth M, Racz K, Tulassay Z. Improvement of bone metabolism after infliximab therapy in Crohn's disease. Orv. Hetil. 146: 1477-1480 (2005).

• Miheller P, Toth M, Pregun I, Tulassay Z. Osteoporosis associated with inflammatory bowel diseases. Orv. Hetil. 145: 1045-1051 (2004).

• Miller PD. Denosumab: anti-RANKL antibody. Curr. Osteoporos. Rep. 7: 18-22 (2009).

• Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study. Liver Transpl. 11: 960-966 (2005). *

• Mills PR, Vallance R, Birnie G, Quigley EM, Main AN, Morgan RJ, Russell RI, Watkinson G. A prospective survey of radiological bone and joint changes in primary biliary cirrhosis. Clin. Radiol. 32: 297-302 (1981).

• Minasyan A, Keisala T, Zou J, Zhang Y, Toppila E, Syvala H, Lou YR, Kalueff AV, Pyykko I, Tuohimaa P. Vestibular dysfunction in vitamin D receptor mutant mice. J. Steroid Biochem. Mol. Biol. 114: 161-166 (2009).

• Mitchison HC, Malcolm AJ, Bassendine MF, James OF. Metabolic bone disease in primary biliary cirrhosis at presentation. Gastroenterology 94: 463-470 (1988).

• Mizoguchi F, Izu Y, Hayata T, Hemmi H, Nakashima K, Nakamura T, Kato S, Miyasaka N, Ezura Y, Noda M. Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption. J. Cell. Biochem. Dec 28 [Epub ahead of print] (2009).

• Molgaard C, Larnkjaer A, Cashman KD, Lamberg-Allardt C, Jakobsen J, Michaelsen KF. Does vitamin D supplementation of healthy Danish Caucasian girls affect bone turnover and bone mineralization? Bone Sep 4 [Epub ahead of print] (2009). *

• Momohara S, Okamoto H, Yago T, Furuya T, Nanke Y, Kotake S, Soejima M, Mizumura T, Ikari K, Tomatsu T. The study of bone mineral density and bone turnover markers in postmenopausal women with active rheumatoid arthritis. Mod. Rheumatol. 15: 410-414 (2005).

• Monegal A, Navasa M, Peris P, Alvarez L, Pons F, Rodes J, Guanabens N. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease. Liver Int. 27: 492-497 (2007). *

• Montalban AG, Boman E, Chang CD, Ceide SC, Dahl R, Dalesandro D, Delaet NG, Erb E, Ernst J, Gibbs A, Kahl J, Kessler L, Lundstrom J, Miller S, Nakanishi H, Roberts E, Saiah E, Sullivan R, Wang Z, Larson CJ. KR-003048, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. Eur. J. Pharmacol. Feb 1 [Epub ahead of print] (2010). *

• Moreira RO, Duarte MP, Farias ML. Disturbances of calcium-PTH-vitamin D axis in chronic liver diseases. Arq. Bras. Endocrinol. Metabol. 48: 443-450 (2004).

• Moreland LW, Curtis JR. Systemic nonarticular manifestations of rheumatoid arthritis: focus on inflammatory mechanisms. Semin. Arthritis Rheum. 39: 132-143 (2009). *

• Moreno ML, Crusius JB, Chernavsky A, Sugai E, Sambuelli A, Vazquez H, Maurino E, Pena AS, Bai JC. The IL-1 gene family and bone involvement in celiac disease. Immunogenetics 57: 618-620 (2005). *

• Morgan SL. Nutrition and bone: it is more than calcium and vitamin D. Womens Health (Lond. Engl.) 5: 727-737 (2009).

• Mori S. Genomic approaches to bone and joint diseases. An order made medical system for management of osteoporosis : an attempt using genetic information. Clin. Calcium 18: 233-238 (2008).

• Mori S, Fuku N, Chiba Y, Tokimura F, Hosoi T, Kimbara Y, Tamura Y, Araki A, Tanaka M, Ito H. Cooperative effect of serum 25-hydroxyvitamin D concentration and a polymorphism of transforming growth factor-beta1 gene on the prevalence of vertebral fractures in postmenopausal osteoporosis. J. Bone Miner. Metab. Jan 7 [Epub ahead of print] (2010). *

• Morita A, Iki M, Dohi Y, Ikeda Y, Kagamimori S, Kagawa Y, Yoneshima H. Effects of the Cdx-2 polymorphism of the vitamin D receptor gene and lifestyle factors on bone mineral density in a representative sample of Japanese women: the Japanese Population-based Osteoporosis (JPOS) Study. Calcif. Tissue Int. 77: 339-347 (2005).

• Morris J, Hawthorne KM, Hotze T, Abrams SA, Hirschi KD. Nutritional impact of elevated calcium transport activity in carrots. Proc. Natl. Acad. Sci. U.S.A. 105: 1431-1435 (2008). *

• Morris ME, Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci. 78: 2116-2130 (2006). *

• Morton AM. Symposium 6: young people, artificial nutrition and transitional care. The nutritional challenges of the young adult with cystic fibrosis: transition. Proc. Nutr. Soc. 68: 430-440 (2009). *

• Mosca M, Carli L, d'Ascanio A, Tani C, Talarico R, Baldini C, Bazzichi L, Tavoni A, Migliorini P, Bombardieri S. Occurrence of organ-specific and systemic autoimmune diseases among the first- and second-degree relatives of Caucasian patients with connective tissue diseases: report of data obtained through direct patient interviews. Clin. Rheumatol. 27: 1045-1048 (2008). *

• Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm. Bowel Dis. 15: 1399-1409 (2009). *

• Moschen AR, Geiger S, Gerner R, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat. Res. Jul 4 [Epub ahead of print] (2009).

• Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54: 479-487 (2005). *

• Moschen AR, Kaser A, Stadlmann S, Millonig G, Kaser S, Muhllechner P, Habior A, Graziadei I, Vogel W, Tilg H. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J. Hepatol. 43: 973-983 (2005). *

• Mounach A, Ouzzif Z, Wariaghli G, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El Maghraoui A. Primary biliary cirrhosis and osteoporosis: a case-control study. J. Bone Miner. Metab. 26: 379-384 (2008). *

• Mouyis M, Ostor AJ, Crisp AJ, Ginawi A, Halsall DJ, Shenker N, Poole KE. Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology (Oxford) 47: 1348-1351 (2008). *

• Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part I. Urol. Oncol. 23: 28-35 (2005).

• Moyad MA. An introduction to dietary/supplemental omega-3 fatty acids for general health and prevention: part II. Urol. Oncol. 23: 36-48 (2005).

• Mulder CJ, Bartelsman JF. Case-finding in coeliac disease should be intensified. Best Pract. Res. Clin. Gastroenterol. 19: 479-486 (2005).

• Mullin BH, Prince RL, Mamotte C, Spector TD, Hart DJ, Dudbridge F, Wilson SG. Further genetic evidence suggesting a role for the RhoGTPase-RhoGEF pathway in osteoporosis. Bone 45: 387-391 (2009). *

• Murray JA. Celiac disease in patients with an affected member, type 1 diabetes, iron-deficiency, or osteoporosis? Gastroenterology 128: S52-S56 (2005). *

• Musialik J, Petelenz M, Gonciarz Z. Effects of alendronate on bone mass in patients with primary biliary cirrhosis and osteoporosis: preliminary results after one year. Scand. J. Gastroenterol. 40: 873-874 (2005). *

• Musumeci M, Vadala G, Tringali G, Insirello E, Roccazzello AM, Simpore J, Musumeci S. Genetic and environmental factors in human osteoporosis from Sub-Saharan to Mediterranean areas. J. Bone Miner. Metab. 27: 424-434 (2009).

• Nagpal S, Na S, Rathnachalam R. Non-calcemic actions of vitamin D receptor ligands. Endocr. Rev. 26: 662-687 (2005). *

• Nakagami H, Tomita N, Kaneda Y, Ogihara T, Morishita R. Anti-oxidant gene therapy by NFkappaB decoy oligodeoxynucleotide. Curr. Pharm. Biotechnol. 7: 95-100 (2006).

• Nakajima A, Doki K, Homma M, Sagae T, Saito R, Ito S, Sumida T, Kohda Y. Investigation of glucocorticoid-induced side effects in patients with autoimmune diseases. Yakugaku Zasshi 129: 445-450 (2009). *

• Nakamura M, Nakamichi Y, Nakamura H, Udagawa N. Osteoclastogenesis and bone resorption. Nippon Rinsho 67: 889-896 (2009).

• Nakchbandi IA, van der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat. Rev. Gastroenterol. Hepatol. 6: 660-670 (2009). *

• Napoli N, Armamento-Villareal R. Estrogen hydroxylation in osteoporosis. Adv. Clin. Chem. 43: 211-227 (2007).

• Napoli N, Rini GB, Serber D, Giri T, Yarramaneni J, Bucchieri S, Camarda L, Di Fede G, Camarda MR, Jain S, Mumm S, Armamento-Villareal R. The Val432Leu polymorphism of the CYP1B1 gene is associated with differences in estrogen metabolism and bone density. Bone 44: 442-448 (2009). *

• Napoli N, Varadharajan A, Rini GB, Del Fiacco R, Yarramaneni J, Mumm S, Villareal DT, Armamento-Villareal RC. Effects of polymorphisms of the sex hormone-binding globulin (SHBG) gene on free estradiol and bone mineral density. Bone 45: 1169-1174 (2009). *

• Nemetz A, Toth M, Garcia-Gonzalez MA, Zagoni T, Feher J, Pena AS, Tulassay Z. Allelic variation at the interleukin 1beta gene is associated with decreased bone mass in patients with inflammatory bowel diseases. Gut 49: 644-649 (2001). *

• Neuberger J. Transplantation for primary biliary cirrhosis. Semin. Liver Dis. 17: 137-146 (1997).

• Newton J, Francis R, Prince M, James O, Bassendine M, Rawlings D, Jones D. Osteoporosis in primary biliary cirrhosis revisited. Gut 49: 282-287 (2001). *

• Newton J, Jones D. Osteoporosis in primary biliary cirrhosis. Panminerva Med. 44: 335-341 (2002).

• Newton JL. Is osteoporosis a specific complication of primary biliary cirrhosis? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 34-35. October 15-16 (2003). *

• Nguyen HD, Bakshi AK, Borum ML. The frequency of osteoporosis screening in men with inflammatory bowel disease. Am. J. Mens Health Feb 2 [Epub ahead of print] (2009).

• Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J. Invest. Dermatol. 129: 1601-1603 (2009). *

• No authors listed. In this issue. Eur. J. Immunol. 39: 2642-2643 (2009).

• No authors listed. Identifying patients with Crohn's disease who are at risk of osteoporosis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 365-366 (2006).

• No authors listed. Etiopathogenesis, diagnostics and treatment of osteoporosis at inflammatory bowel diseases. Eksp. Klin. Gastroenterol. 3: 8-14, 100 (2005).

• Noble CL, McCullough J, Ho W, Lees CW, Nimmo E, Drummond H, Bear S, Hannan J, Millar C, Ralston S, Satsangi J. Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 27: 588-596 (2008). *

• Noda M, Rodan GA. Transcriptional regulation of osteopontin production in rat osteoblast-like cells by parathyroid hormone. J. Cell Biol. 108: 713-718 (1989).

• Noda M, Vogel RL, Craig AM, Prahl J, DeLuca HF, Denhardt DT. Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. Proc. Natl. Acad. Sci. U.S.A. 87: 9995-9999 (1990). *

• Noda M, Yoon K, Prince CW, Butler WT, Rodan GA. Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. J. Biol. Chem. 263: 13916-13921 (1988). *

• Norek A, Romanowska-Pietrasiak B, Bal J. Genetic markers in the pathogenesis of osteopenia and osteoporosis in cystic fibrosis. Med. Wieku. Rozwoj. X: 275-287 (2006).

• Novoa Medina Y, Lopez-Capape M, Lara Orejas E, Alonso Blanco M, Camarero Salces C, Barrio Castellanos R. Impact of diagnosis of celiac disease on metabolic control of type 1 diabetes. An. Pediatr. (Barc.) 68: 13-17 (2008).

• O'Sullivan M, O'Morain C. Nutrition in inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 20: 561-573 (2006).

• Oberholzer J, Al-Saghier M, Kneteman NM. Steroid avoidance in liver transplantation. Can. J. Gastroenterol. 18 Suppl. C: 5C-11C (2004).

• Oelzner P, Franke S, Lehmann G, Eidner T, Muller A, Wolf G, Hein G. Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover. Clin. Rheumatol. 26: 2127-2135 (2007). *

• Ofodile ON. Cardiovascular disease could be contained based on currently available data! Dose Response 4: 225-254 (2006).

• Ohashi T, Ichimura S, Mochizuki Y, Miura T, Mogushi K, Ohashi W, Sato Y, Kojima R, Tanaka H, Igarashi Y, Nomura F, Katayama K, Miki T, Nishizawa Y. The mechanism of TRACP 5b maturation. Rinsho Byori 55: 325-329 (2007).

• Okada H, Takenaka R, Hiraoka S, Makidono C, Hori SI, Kato J, Okazaki H, Kawamoto H, Mizuno M, Shiratori Y. Centrifugal leukocytapheresis therapy for ulcerative colitis without concurrent corticosteroid administration. Ther. Apher. Dial. 10: 242-246 (2006). *

• Okada Y, Nawata M, Tanaka Y. Secondary osteoporosis. Efficacy of anti-cytokines therapy and anti-RANKL antibody in RA. Clin. Calcium 17: 1762-1768 (2007).

• Olsson R, Mattsson LA, Obrant K, Mellstrom D. Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis. Liver 19: 188-192 (1999).

• Omoigui S. The Interleukin-6 inflammation pathway from cholesterol to aging - role of statins, bisphosphonates and plant polyphenols in aging and age-related diseases. Immun. Ageing 4: 1 (2007). *

• Ongphiphadhanakul B. Osteoporosis: the role of genetics and the environment. Forum Nutr. 60: 158-167 (2007).

• Orchard T. Extraintestinal complications of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 512-517 (2003).

• Orlic ZC, Turk T, Sincic BM, Stimac D, Cvijanovic O, Maric I, Tomas MI, Jurisic-Erzen D, Licul V, Bobinac D. How activity of inflammatory bowel disease influences bone loss. J. Clin. Densitom. 13: 36-42 (2010).

• Ormarsdottir S, Mallmin H, Naessen T, Petren-Mallmin M, Broome U, Hultcrantz R, Loof L. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J. Intern. Med. 256: 63-69 (2004). *

• Ortego-Centeno N, Munoz-Torres M, Callejas-Rubio JL, Riera-Montes M. Etidronate and glucocorticoid induced osteoporosis. J. Rheumatol. 32: 199-200 (2005).

• Osmancevic A, Landin-Wilhelmsen K, Larko O, Mellstrom D, Wennberg AM, Hulthen L, Krogstad AL. Risk factors for osteoporosis and bone status in postmenopausal women with psoriasis treated with UVB therapy. Acta Derm. Venereol. 88: 240-246 (2008).

• Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B. The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif. Tissue Int. Dec 1 [Epub ahead of print] (2009).

• Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58: 389-462 (2006). *

• Palicka V. Celiac disease and osteoporosis - is the link close enough to call for action? Vnitr. Lek. 53: 1243-1244 (2007).

• Palicka V. Drugs influencing bone metabolism in diabetic patients. Vnitr. Lek. 55: 368-370 (2009).

• Palou A. New challenges in basic and applied nutrition. Rev. Med. Univ. Navarra 50: 62-70 (2006).

• Papaioannou A, Ferko NC, Adachi JD. All patients with inflammatory bowel disease should have bone density assessment: pro. Inflamm. Bowel Dis. 7: 158-162 (2001). *

• Papamichael KX, Papaioannou G, Karga H, Roussos A, Mantzaris GJ. Helicobacter pylori infection and endocrine disorders: is there a link? World J. Gastroenterol. 15: 2701-2707 (2009). *

• Pares A, Guanabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. Clin. Liver Dis. 12: 407-424 (2008).

• Pares A, Guanabens N, Alvarez L, De Osaba MJ, Oriola J, Pons F, Caballeria L, Monegal A, Salvador G, Jo J, Peris P, Rivera F, Ballesta AM, Rodes J. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology 33: 554-560 (2001). *

• Pares A, Guanabens N, Rodes J. Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 17: 311-315 (2005).

• Park OJ, Shin SY, Choi Y, Kim MH, Chung CP, Ku Y, Kim KK. The association of osteoprotegerin gene polymorphisms with periodontitis. Oral Dis. 14: 440-444 (2008).

• Pazianas M, Rhim AD, Weinberg AM, Su C, Lichtenstein GR. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease. Ann. N. Y. Acad. Sci. 1068: 543-556 (2006). *

• Pedersen PL. Transport ATPases into the year 2008: a brief overview related to types, structures, functions and roles in health and disease. J. Bioenerg. Biomembr. 39: 349-355 (2007). *

• Pedone C, Napoli N, Pozzilli P, Lauretani F, Bandinelli S, Ferrucci L, Antonelli-Incalzi R. Quality of diet and potential renal acid load as risk factors for reduced bone density in elderly women. Bone Dec 14 [Epub ahead of print] (2009). *

• Pelczynska K, Jaroszewicz I, Switalska M, Opolski A. Biological activity of calcitriol and its new analogues - potential therapeutic applications. Postepy. Hig. Med. Dosw. (Online) 59: 129-139 (2005).

• Penolazzi L, Magri E, Lambertini E, Calo G, Cozzani M, Siciliani G, Piva R, Gambari R. Local in vivo administration of a decoy oligonucleotide targeting NF-kappaB induces apoptosis of osteoclasts after application of orthodontic forces to rat teeth. Int. J. Mol. Med. 18: 807-811 (2006). *

• Peppone LJ, Hebl S, Purnell JQ, Reid ME, Rosier RN, Mustian KM, Palesh OG, Huston AJ, Ling MN, Morrow GR. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos. Int. Dec 4 [Epub ahead of print] (2009). *

• Perakyla M, Malinen M, Herzig KH, Carlberg C. Gene regulatory potential of non-steroidal vitamin D receptor ligands. Mol. Endocrinol. 19: 2060-2073 (2005). *

• Pereira CC, Correa PH, Halpern A. Case report: recently diagnosed celiac disease as aggravating factor of osteoporosis in old woman. Arq. Bras. Endocrinol. Metabol. 50: 1127-1132 (2006).

• Pereira FA, Facincani I, Jorgetti V, Ramalho LN, Volpon JB, Dos Reis LM, de Paula FJ. Etiopathogenesis of hepatic osteodystrophy in Wistar rats with cholestatic liver disease. Calcif. Tissue Int. 85: 75-83 (2009).

• Pereira SP, Bray GP, Pitt PI, Li F, Moniz C, Williams R. Non-invasive assessment of bone density in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 11: 323-328 (1999).

• Pereira SP, O'Donohue J, Moniz C, Phillips MG, Abraha H, Buxton-Thomas M, Williams R. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial. Aliment. Pharmacol. Ther. 19: 563-570 (2004). *

• Peterlik M, Cross HS. Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology. Eur. J. Clin. Nutr. 63: 1377-1386 (2009). *

• Petramala L, Acca M, Francucci CM, D'Erasmo E. Hyperhomocysteinemia: a biochemical link between bone and cardiovascular system diseases? J. Endocrinol. Invest. 32: S10-S14 (2009).

• Pettus LH, Xu S, Cao GQ, Chakrabarti PP, Rzasa RM, Sham K, Wurz RP, Zhang D, Middleton S, Henkle B, Plant MH, Saris CJ, Sherman L, Wong LM, Powers DA, Tudor Y, Yu V, Lee MR, Syed R, Hsieh F, Tasker AS. 3-Amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase. J. Med. Chem. 51: 6280-6292 (2008). *

• Phillips K, Aliprantis A, Coblyn J. Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. Drugs Aging 23: 773-779 (2006).

• Pinkerton JV, Dalkin AC, Crowe SE, Wilson BB, Stelow EB. Treatment of postmenopausal osteoporosis in a patient with celiac disease. Nat. Rev. Endocrinol. 6: 167-171 (2010).

• Pistorius LR, Sweidan WH, Purdie DW, Steel SA, Howey S, Bennett JR, Sutton DR. Coeliac disease and bone mineral density in adult female patients. Gut 37: 639-642 (1995). *

• Pivonello R, De Martino MC, De Leo M, Tauchmanova L, Faggiano A, Lombardi G, Colao A. Cushing's syndrome: aftermath of the cure. Arq. Bras. Endocrinol. Metabol. 51: 1381-1391 (2007). *

• Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39: 443-452 (2006). *

• Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am. J. Gastroenterol. 93: 1483-1490 (1998). *

• Pollanen R, Sillat T, Pajarinen J, Levon J, Kaivosoja E, Konttinen YT. Microbial antigens mediate HLA-B27 diseases via TLRs. J. Autoimmun. 32: 172-177 (2009).

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Poupon R. Primary biliary cirrhosis. Schweiz. Med. Wochenschr. 121: 727-732 (1991).

• Poupon R. Primary biliary cirrhosis: a 2010 update. J. Hepatol. [In Press] (2010).

• Presutti RJ, Cangemi JR, Cassidy HD, Hill DA. Celiac disease. Am. Fam. Physician 76: 1795-1802 (2007). *

• Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2: CD003778 (2005). *

• Pritchett JW. Statins and dietary fish oils improve lipid composition in bone marrow and joints. Clin. Orthop. Relat. Res. 456: 233-237 (2007).

• Qasim A, Seery J, Morain CA. Osteoporosis in newly diagnosed inflammatory bowel disease. Gastroenterology 121: 504-506 (2001). *

• Quarta L, Corrado A, Melillo N, Cantatore FP. Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. Ann. Ital. Med. Int. 20: 211-217 (2005).

• Radojkovic I, Radojkovic J, Djurica S. Diagnosis of osteoporosis occurring in autoimmune thyroid gland disease. Srp. Arh. Celok. Lek. 133 Suppl. 1: 40-45 (2005).

• Radovanovic-Dinic B, Nagorni A, Katic V, Bjelakovic G. Clinical extraintestinal manifestations of ulcerative colitis. Facta Universitatis Series: Medicine and Biology 10: 139-144 (2003). *

• Rahman MM, Bhattacharya A, Fernandes G. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid. J. Cell. Physiol. 214: 201–209 (2008). *

• Rahman MM, Bhattacharya A, Fernandes G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling. J. Lipid Res. 47: 1739-1748 (2006). *

• Rammert Ch, Kullak-Ublick GA. Management of ulcerative colitis. Ther. Umsch. 60: 145-150 (2003).

• Ranganathan P. Genetics of bone loss in rheumatoid arthritis - role of vitamin D receptor polymorphisms. Rheumatology (Oxford) 48: 342-346 (2009). *

• Rapuri PB, Gallagher JC, Nawaz Z. Caffeine decreases vitamin D receptor protein expression and 1,25(OH)(2)D(3) stimulated alkaline phosphatase activity in human osteoblast cells. J. Steroid Biochem. Mol. Biol. 103: 368-371 (2007).

• Rass P, Pakozdi A, Lakatos P, Zilahi E, Sipka S, Szegedi G, Szekanecz Z. Vitamin D receptor gene polymorphism in rheumatoid arthritis and associated osteoporosis. Rheumatol. Int. 26: 964-971 (2006). *

• Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int. Arch. Allergy Immunol. 143: 31-48 (2006). *

• Rauner M, Stupphann D, Haas M, Fert I, Glatigny S, Sipos W, Breban M, Pietschmann P. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio. J. Rheumatol. 36: 120-126 (2009).

• Rautemaa R, Lauhio A, Cullinan MP, Seymour GJ. Oral infections and systemic disease - an emerging problem in medicine. Clin. Microbiol. Infect. 13: 1041-1047 (2007). *

• Reddy SI, Friedman S, Telford JJ, Strate L, Ookubo R, Banks PA. Are patients with inflammatory bowel disease receiving optimal care? Am. J. Gastroenterol. 100: 1357-1361 (2005). *

• Reichel C, Meier-Abt PJ. Cholestatic liver diseases. Ther. Umsch. 54: 639-644 (1997).

• Reinshagen M. Osteoporosis in inflammatory bowel disease. Journal of Crohn's and Colitis 2: 202-207 (2008).

• Reinshagen M, Von Tirpitz C. Diagnosis and management of osteoporosis in inflammatory bowel disease. Minerva Med. 95: 481-487 (2004).

• Ribaya-Mercado JD, Blumberg JB. Vitamin A: is it a risk factor for osteoporosis and bone fracture? Nutr. Rev. 65: 425-438 (2007). *

• Richert L, Chevalley T, Manen D, Bonjour JP, Rizzoli R, Ferrari S. Bone mass in prepubertal boys is associated with a Gln223Arg amino acid substitution in the leptin receptor. J. Clin. Endocrinol. Metab. 92: 4380-4386 (2007). *

• Riches PL, McRorie E, Fraser WD, Determann C, van't Hof R, Ralston SH. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N. Engl. J. Med. 361: 1459-1465 (2009). *

• Richy F, Deroisy R, Lecart MP, Hanssens L, Mawet A, Reginster JY. D-Hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin. Exp. Res. 17: 133-142 (2005).

• Ricketts ML, Moore DD, Banz WJ, Mezei O, Shay NF. Molecular mechanisms of action of the soy isoflavones includes activation of promiscuous nuclear receptors. A review. J. Nutr. Biochem. 16: 321-330 (2005). *

• Ridker PM, Chasman DI, Zee RY, Parker A, Rose L, Cook NR, Buring JE; Women's Genome Health Study Working Group. Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy American women. Clin. Chem. 54: 249-255 (2008). *

• Rifas L, Weitzmann MN. A novel T cell cytokine, secreted osteoclastogenic factor of activated T cells, induces osteoclast formation in a RANKL-Independent manner. Arthritis Rheum. 60: 3324-3335 (2009). *

• Robitaille J, Yoon PW, Moore CA, Liu T, Irizarry-Delacruz M, Looker AC, Khoury MJ. Prevalence, family history, and prevention of reported osteoporosis in U.S. women. Am. J. Prev. Med. 35: 47-54 (2008). *

• Roblin X, Bonaz B. Osteoporosis and inflammatory bowel disease. Am. J. Gastroenterol. 102: 209 (2007). *

• Roblin X, Phelip JM, Genevois M, Ducros V, Bonaz B. Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn's disease. Aliment. Pharmacol. Ther. 25: 797-804 (2007). *

• Rodan SB, Wesolowski G, Hilton DJ, Nicola NA, Rodan GA. Leukemia inhibitory factor binds with high affinity to preosteoblastic RCT-1 cells and potentiates the retinoic acid induction of alkaline phosphatase. Endocrinology 127: 1602-1608 (1990).

• Rodan SB, Wesolowski G, Yoon K, Rodan GA. Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2.8 cells. J. Biol. Chem. 264: 19934-19941 (1989). *

• Rodino MA, Shane E. Osteoporosis after organ transplantation. Am. J. Med. 104: 459-469 (1998). *

• Rodrigo L. Celiac disease. World J. Gastroenterol. 12: 6585-6593 (2006). *

• Rodriguez Nieva N, Febrer Rotger A, Melendez Plumed M, Vernet Bori A. Osteoarthropathy in three siblings with Wilsons disease. An. Pediatr. (Barc.) 61: 181-184 (2004).

• Rodriguez-Bores L, Barahona-Garrido J, Yamamoto-Furusho JK. Basic and clinical aspects of osteoporosis in inflammatory bowel disease. World J. Gastroenterol. 13: 6156-6165 (2007). *

• Rodriguez-Reyna TS, Martinez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. World J. Gastroenterol. 15: 5517-5524 (2009). *

• Rogler G, Scholmerich J. Extraintestinal manifestations of inflammatory bowel disease. Med. Klin. (Munich) 99: 123-130 (2004).

• Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Teltscher M. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am. J. Gastroenterol. 96: 2143-2149 (2001). *

• Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 30: 340-346 (2002). *

• Romero DF, Buchinsky FJ, Rucinski B, Cvetkovic M, Bryer HP, Liang XG, Ma YF, Jee WS, Epstein S. Rapamycin: a bone sparing immunosuppressant? J. Bone Miner. Res. 10: 760-768 (1995).

• Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee Meeting. N. Engl. J. Med. 357: 844-846 (2007). *

• Rosen CJ, Black DM, Greenspan SL. Vignettes in osteoporosis: a road map to successful therapeutics. J. Bone Miner. Res. 19: 3-10 (2004).

• Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Adv. Ther. 26: 40-54 (2009).

• Rossini M, Viapiana O, Del Marco A, de Terlizzi F, Gatti D, Adami S. Quantitative ultrasound in adults with cystic fibrosis: correlation with bone mineral density and risk of vertebral fractures. Calcif. Tissue Int. 80: 44-49 (2007). *

• Rost D, Kulaksiz H, Stiehl A. Treatment of primary sclerosing cholangitis. Curr. Treat. Options Gastroenterol. 10: 111-119 (2007).

• Roth J, Bechtold S, Borte G, Dressler F, Girschick HJ, Borte M. Osteoporosis in juvenile idiopathic arthritis - a practical approach to diagnosis and therapy. Eur. J. Pediatr. 166: 775-784 (2007).

• Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J. Gastroenterol. 12: 4819-4831 (2006). *

• Roumestan C, Gougat C, Jaffuel D, Mathieu M. Glucocorticoids and their receptor: mechanisms of action and clinical implications. Rev. Med. Interne. 25: 636-647 (2004).

• Rousseau JC, Delmas PD. Biological markers in osteoarthritis. Nat. Clin. Pract. Rheumatol. 3: 346-356 (2007). *

• Rovensky J. Rheumatic diseases and Klinefelter's syndrome. Autoimmun. Rev. 6: 33-36 (2006).

• Roztoczynska D, Starzyk J. The role of a pediatric endocrinologist in diagnostics and therapeutic management of anorexia nervosa - own experiences and review of literature. Przegl. Lek. 66: 52-57 (2009).

• Rubin KR. Turner syndrome: transition from pediatrics to adulthood. Endocr. Pract. 14: 775-781 (2008).

• Rude RK, Wei L, James Norton H, Lu SS, Dempster DW, Gruber HE. TNFalpha receptor knockout in mice reduces adverse effects of magnesium deficiency on bone. Growth Factors 27: 370-376 (2009).

• Ruiz-Gaspa S, Guanabens N, Enjuanes A, Peris P, Martinez-Ferrer A, de Osaba MJ, Gonzalez B, Alvarez L, Monegal A, Combalia A, Pares A. Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur. J. Clin. Invest. 40: 25-34 (2010). *

• Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214 (2006). *

• Ryan BM, Russel MG, Schurgers L, Wichers M, Sijbrandij J, Stockbrugger RW, Schoon E. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment. Pharmacol. Ther. 20: 851-857 (2004). *

• Ryan JG, Morgan RK, Lavin PJ, Murray FE, O'Connell PG. Current management of corticosteroid-induced osteoporosis: variations in awareness and management. Ir. J. Med. Sci. 173: 20-22 (2004).

• Saeed Z, Guilbault C, De Sanctis JB, Henri J, Marion D, St-Arnaud R, Radzioch D. Fenretinide prevents the development of osteoporosis in Cftr-KO mice. J. Cyst. Fibros. 7: 222-230 (2008).

• Saibeni S, Lecchi A, Meucci G, Cattaneo M, Tagliabue L, Rondonotti E, Formenti S, De Franchis R, Vecchi M. Prevalence of hyperhomocysteinemia in adult gluten-sensitive enteropathy at diagnosis: role of B12, folate, and genetics. Clin. Gastroenterol. Hepatol. 3: 574-580 (2005).

• Saito N. Creation of highly potent vitamin D receptor antagonists. Yakugaku Zasshi 127: 1215-1222 (2007).

• Sakellariou GT, Moschos J, Berberidis C, Mpoumponaris A, Kadis S, Molyvas E, Kouklakis G. Bone density in young males with recently diagnosed inflammatory bowel disease. Joint Bone Spine 73: 725-728 (2006). *

• Saldeen P, Saldeen T. Women and omega-3 fatty acids. Obstet. Gynecol. Surv. 59: 722-730 (2004).

• Salviano FN, Burgos MG, Santos EC. Socioeconomic and nutritional profile of patients with inflammatory bowel disease at a university hospital. Arq. Gastroenterol. 44: 99-106 (2007).

• Sanchez AJ, Aranda-Michel J. Liver disease and osteoporosis. Nutr. Clin. Pract. 21: 273-278 (2006). *

• Sandborn WJ. Steroid-dependent Crohn's disease. Can. J. Gastroenterol. 14 Suppl. C: 17C-22C (2000).

• Sandhu BS, Luketic VA. Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849 (2006). *

• Sansoni P, Vescovini R, Fagnoni F, Biasini C, Zanni F, Zanlari L, Telera A, Lucchini G, Passeri G, Monti D, Franceschi C, Passeri M. The immune system in extreme longevity. Exp. Gerontol. 43: 61-65 (2008).

• Santini D, Fratto ME, Vincenzi B, La Cesa A, Dianzani C, Tonini G. Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities. BioDrugs 18: 269-278 (2004).

• Sapone N, Pellicano R, Simondi D, Sguazzini C, Reggiani S, Terzi E, Rizzetto M, Astegiano M. A 2008 panorama on osteoporosis and inflammatory bowel disease. Minerva Med. 99: 65-71 (2008).

• Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 96: 23-43 (2002). *

• Schacke H, Hennekes H, Schottelius A, Jaroch S, Lehmann M, Schmees N, Rehwinkel H, Asadullah K. SEGRAs: a novel class of anti-inflammatory compounds. Ernst. Schering Res. Found. Workshop 40: 357-371 (2002).

• Scharla SH, Minne HW, Lempert UG, Leidig G, Hauber M, Raedsch R, Ziegler R. Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis). Exp. Clin. Endocrinol. 102: 44-49 (1994).

• Scharla SH, Schacht E, Lempert UG. Alfacalcidol versus plain vitamin D in inflammation induced bone loss. J. Rheumatol. Suppl. 76: 26-32 (2005).

• Scherer JR. Celiac disease. Drugs Today (Barc.) 44: 75-88 (2008).

• Schinke T, Schilling AF, Baranowsky A, Seitz S, Marshall RP, Linn T, Blaeker M, Huebner AK, Schulz A, Simon R, Gebauer M, Priemel M, Kornak U, Perkovic S, Barvencik F, Beil FT, Del Fattore A, Frattini A, Streichert T, Pueschel K, Villa A, et al. Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat. Med. 15: 674-681 (2009). *

• Schmidt A, Vogel R, Rutledge SJ, Opas EE, Rodan GA, Friedman E. Cross-talk between an activator of nuclear receptors-mediated transcription and the D(1) dopamine receptor signaling pathway. Pharmacol. Biochem. Behav. 80: 379-385 (2005). *

• Schneider S, Schmitt G, Richter W. Prevalence and correlates of inflammatory arthritis in Germany: data from the First National Health Survey. Rheumatol. Int. 27: 29-38 (2006). *

• Schneider SM, Al-Jaouni R, Filippi J, Wiroth JB, Zeanandin G, Arab K, Hebuterne X. Sarcopenia is prevalent in patients with Crohn's disease in clinical remission. Inflamm. Bowel Dis. 14: 1562-1568 (2008). *

• Schoon EJ, Bollani S, Mills PR, Israeli E, Felsenberg D, Ljunghall S, Persson T, Hapten-White L, Graffner H, Bianchi Porro G, Vatn M, Stockbrugger RW. Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin. Gastroenterol. Hepatol. 3: 113-121 (2005). *

• Schoon EJ, Muller MC, Vermeer C, Schurgers LJ, Brummer RJ, Stockbrugger RW. Low serum and bone vitamin K status in patients with longstanding Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 48: 473-477 (2001). *

• Schroeder TM, Westendorf JJ. Histone deacetylase inhibitors promote osteoblast maturation. J. Bone Miner. Res. 20: 2254-2263 (2005). *

• Schrumpf E, Boberg KM. Standard treatment of PSC and overlap AIH/PSC. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 71 (2004). *

• Schulte C, Dignass AU, Mann K, Goebell H. Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand. J. Gastroenterol. 34: 696-702 (1999). *

• Schulte C, Dignass AU, Mann K, Goebell H. Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 4: 268-275 (1998). *

• Schulte CM. Bone disease in inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 43-49 (2004). *

• Schulte CM, Dignass AU, Goebell H, Roher HD, Schulte KM. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 119: 909-920 (2000). *

• Schuppan D. Progress of knowledge of immunopathogenesis in celiac disease. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 59-60. September 12 - 13 (2003). *

• Schuppan D. Current concepts in celiac disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 55 (2005). *

• Schwartz AV, Sellmeyer DE. Effect of thiazolidinediones on skeletal health in women with type 2 diabetes. Expert Opin. Drug Saf. 7: 69-78 (2008).

• Schwartz DA, Connolley CD, Koyama T, Wise PE, Herline AJ. Calcaneal ultrasound bone densitometry is not a useful tool to screen patients with inflammatory bowel disease at high risk for metabolic bone disease. Inflamm. Bowel Dis. 11: 749-754 (2005). *

• Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 46 Suppl. 1: i1-i8 (2000). *

• Scott EM, Scott BB. A strategy for osteoporosis in gastroenterology. Eur. J. Gastroenterol. Hepatol. 10: 689-696 (1998).

• Seales EC, Micoli KJ, McDonald JM. Calmodulin is a critical regulator of osteoclastic differentiation, function, and survival. J. Cell. Biochem. 97: 45-55 (2006). *

• Seidel MF, Herguijuela M, Forkert R, Otten U. Nerve growth factor in rheumatic diseases. Semin. Arthritis Rheum. May 27 [Epub ahead of print] (2009). *

• Seishima M, Mizutani Y, Shibuya Y, Nagasawa C, Aoki T. Efficacy of granulocyte and monocyte adsorption apheresis for pustular psoriasis. Ther. Apher. Dial. 12: 13-18 (2008).

• Selvaggi G, Weppler D, Tzakis A. Liver and gastrointestinal transplantation at the University of Miami. Clin. Transpl. 2003: 255-266 (2003).

• Seremak-Mrozikiewicz A, Drews K, Mrozikiewicz PM, Bartkowiak-Wieczorek J, Marcinkowska M, Wawrzyniak A, Slomski R, Kalak R, Czerny B, Horst-Sikorska W. Correlation of vitamin D receptor gene (VDR) polymorphism with osteoporotic changes in Polish postmenopausal women. Neuro. Endocrinol. Lett. Dec 14 [Epub ahead of print] (2009).

• Seriolo B, Paolino S, Sulli A, Cutolo M. Are there any positive effects of TNF-alpha blockers on bone metabolism? Reumatismo 58: 199-205 (2006).

• Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann. N. Y. Acad. Sci. 1069: 420-427 (2006). *

• Sermet-Gaudelus I, Castanet M, Retsch-Bogart G, Aris RM. Update on cystic fibrosis-related bone disease: a special focus on children. Paediatr. Respir. Rev. 10: 134-142 (2009).

• Sermet-Gaudelus I, Nove-Josserand R, Loeille GA, Dacremont G, Souberbielle JC, Fritsch J, Laurans M, Moulin P, Cortet B, Salles JP, Ginies JL, Guillot M, Perez-Martin S, Ruiz JC, Montagne V, Cohen-Solal M, Cormier C, Garabedian M, Mallet E. Recommandations for the management of bone demineralization in cystic fibrosis. Arch. Pediatr. 15: 301-312 (2008).

• Shead EF, Haworth CS, Barker H, Bilton D, Compston JE. Osteoclast function, bone turnover and inflammatory cytokines during infective exacerbations of cystic fibrosis. J. Cyst. Fibros. Dec 14 [Epub ahead of print] (2009).

• Shearer MJ, Newman P. Metabolism and cell biology of vitamin K. Thromb. Haemost. 100: 530-547 (2008).

• Shih MS, Anderson C. Does "hepatic osteodystrophy" differ from peri- and postmenopausal osteoporosis? A histomorphometric study. Calcif. Tissue Int. 41: 187-191 (1987).

• Shimokata H, Ando F. Genomic approaches to bone and joint diseases. Current state of disease genome research: osteoporosis. Clin. Calcium 18: 155-161 (2008).

• Shinohara M, Koga T, Okamoto K, Sakaguchi S, Arai K, Yasuda H, Takai T, Kodama T, Morio T, Geha RS, Kitamura D, Kurosaki T, Ellmeier W, Takayanagi H. Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell 132: 794-806 (2008). *

• Shiomi S, Masaki K, Habu D, Takeda T, Nishiguchi S, Kuroki T, Ochi H. Calcitriol for bone loss in patients with primary biliary cirrhosis. J. Gastroenterol. 34: 241-245 (1999).

• Shiraki M, Urano T, Kuroda T, Saito M, Tanaka S, Miyao-Koshizuka M, Inoue S. The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J. Bone Miner. Metab. 26: 595-602 (2008). *

• Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann. N. Y. Acad. Sci. 1056: 206-217 (2005). *

• Sibley E. Carbohydrate intolerance. Curr. Opin. Gastroenterol. 20: 162-167 (2004).

• Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Seinhart H, Greenberg G. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm. Bowel Dis. 10: 220-228 (2004). *

• Siffledeen JS, Fedorak RN, Siminoski K, Jen H, Vaudan E, Abraham N, Steinhart H, Greenberg G. Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn's disease. Clin. Gastroenterol. Hepatol. 3: 122-132 (2005). *

• Siffledeen JS, Siminoski K, Steinhart H, Greenberg G, Fedorak RN. The frequency of vitamin D deficiency in adults with Crohn's disease. Can. J. Gastroenterol. 17: 473-478 (2003). *

• Silva RG, Pippa MG, Zerbin CA. Evaluation of body composition and bone mineral density in women with rheumatoid arthritis. Rev. Assoc. Med. Bras. 53: 135-141 (2007).

• Simopoulos AP. Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed. Pharmacother. 60: 502-507 (2006).

• Simula MP, Cannizzaro R, Marin MD, Pavan A, Toffoli G, Canzonieri V, De Re V. Two-dimensional gel proteome reference map of human small intestine. Proteome Sci. 7: 10 (2009). *

• Sioka C, Kyritsis AP, Fotopoulos A. Multiple sclerosis, osteoporosis, and vitamin D. J. Neurol. Sci. 287: 1-6 (2009).

• Sipos W, Pietschmann P, Rauner M. Strategies for novel therapeutic approaches targeting cytokines and signaling pathways of osteoclasto- and osteoblastogenesis in the fight against immune-mediated bone and joint diseases. Curr. Med. Chem. 15: 127-136 (2008).

• Soen S. Daily practice along the guideline for prevention and treatment of osteoporosis. The effects of anti-TNF therapy on bone and joint manifestations in rheumatoid arthritis. Clin. Calcium 18: 1169-1175 (2008).

• Sokhi RP, Anantharaju A, Kondaveeti R, Creech SD, Islam KK, Van Thiel DH. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl. 10: 648-653 (2004). *

• Solaymani-Dodaran M, Card TR, Aithal GP, West J. Fracture risk in people with primary biliary cirrhosis: a population based cohort study. Gastroenterology 131: 1752-1757 (2006). *

• Solerio E, Isaia G, Innarella R, Di Stefano M, Farina M, Borghesio E, Framarin L, Rizzetto M, Rosina F. Osteoporosis: still a typical complication of primary biliary cirrhosis? Dig. Liver Dis. 35: 339-346 (2003).

• Solomon DH, Katz JN, Cabral D, Patrick AR, Bukowski JF, Coblyn JS. Osteoporosis management in patients with rheumatoid arthritis: evidence for improvement. Arthritis Rheum. 55: 873-877 (2006). *

• Soltanoff CS, Yang S, Chen W, Li YP. Signaling networks that control the lineage commitment and differentiation of bone cells. Crit. Rev. Eukaryot. Gene Expr. 19: 1-46 (2009).

• Sommer P, Ray DW. Novel therapeutic agents targeting the glucocorticoid receptor for inflammation and cancer. Curr. Opin. Investig. Drugs 9: 1070-1077 (2008).

• Souberbielle JC, Friedlander G, Kahan A, Cormier C. Evaluating vitamin D status. Implications for preventing and managing osteoporosis and other chronic diseases. Joint Bone Spine 73: 249-253 (2006). *

• Souto JC, Blanco-Vaca F, Soria JM, Buil A, Almasy L, Ordonez-Llanos J, M Martin-Campos J, Lathrop M, Stone W, Blangero J, Fontcuberta J. A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project. Am. J. Hum. Genet. 76: 925-933 (2005). *

• Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin. Chim. Acta 372: 33-42 (2006). *

• Sperandeo MP, Annunziata P, Bozzato A, Piccolo P, Maiuri L, D'Armiento M, Ballabio A, Corso G, Andria G, Borsani G, Sebastio G. SLC7A7 disruption causes fetal growth retardation by down-regulating Igf1 in the mouse model of lysinuric protein intolerance. Am. J. Physiol. Cell Physiol. 293: C191-C198 (2007). *

• Springer JE, Cole DE, Rubin LA, Cauch-Dudek K, Harewood L, Evrovski J, Peltekova VD, Heathcote EJ. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 118: 145-151 (2000). *

• Stabler A, Schmidt D, Schnabelmeier H, Reiser M. Fatigue fractures of the sacrum in primary biliary liver cirrhosis. Aktuelle. Radiol. 5: 161-163 (1995).

• Stava CJ, Jimenez C, Hu MI, Vassilopoulou-Sellin R. Skeletal sequelae of cancer and cancer treatment. J. Cancer Surviv. 3: 75-88 (2009).

• Stazi AV, Mantovani A. Celiac disease and its endocrine and nutritional implications on male reproduction. Minerva Med. 95: 243-254 (2004).

• Stazi AV, Trecca A, Trinti B. Osteoporosis in celiac disease and in endocrine and reproductive disorders. World J. Gastroenterol. 14: 498-505 (2008). *

• Stazi AV, Trinti B. Reproductive aspects of celiac disease. Ann. Ital. Med. Int. 20: 143-157 (2005).

• Stazi AV, Trinti B. Risk of osteoporosis in endocrine disorders and celiac disease. Ann. Ist Super Sanita. 43: 430-433 (2007).

• Stazi AV, Trinti B. Reproduction, endocrine disorders and celiac disease: risk factors of osteoporosis. Minerva Med. 97: 191-203 (2006).

• Stellon AJ, Davies A, Compston J, Williams R. Osteoporosis in chronic cholestatic liver disease. Q. J. Med. 57: 783-790 (1985).

• Stellon AJ, Webb A, Compston J, Williams R. Lack of osteomalacia in chronic cholestatic liver disease. Bone 7: 181-185 (1986).

• Stern PH. The calcineurin-NFAT pathway and bone: intriguing new findings. Mol. Interv. 6: 193-196 (2006). *

• Stevenson CL. Advances in peptide pharmaceuticals. Curr. Pharm. Biotechnol. 10: 122-137 (2009).

• Stewart TL, Jin H, McGuigan FE, Albagha OM, Garcia-Giralt N, Bassiti A, Grinberg D, Balcells S, Reid DM, Ralston SH. Haplotypes defined by promoter and intron 1 polymorphisms of the COLIA1 gene regulate bone mineral density in women. J. Clin. Endocrinol. Metab. 91: 3575-3583 (2006). *

• Stiger F, Brändstrom H, Gillberg P, Melhus H, Wolk A, Michaelsson K, Kindmark A. Association between repeat length of exon 1 CAG microsatellite in the androgen receptor and bone density in men is modulated by sex hormone levels. Calcif. Tissue Int. 82: 427-435 (2008).

• Still K, Grabowski P, Mackie I, Perry M, Bishop N. The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif. Tissue Int. 83: 285-292 (2008).

• Stokkers PC, Deley M, Spek MV, Verberne HJ, Van Deventer SJ, Hommes DW. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. Scand. J. Gastroenterol. 41: 200-204 (2006). *

• Strandberg L, Lorentzon M, Hellqvist A, Nilsson S, Wallenius V, Ohlsson C, Jansson JO. Interleukin-1 system gene polymorphisms are associated with fat mass in young men. J. Clin. Endocrinol. Metab. 91: 2749-2754 (2006). *

• Strassburg CP. Autoimmune liver diseases. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 66-70 (2005). *

• Stuckey C, Lowdon J, Howdle P. Joint BAPEN and British Society of Gastroenterology Symposium on 'Coeliac disease: basics and controversies'. Dietitians are better than clinicians in following up coeliac disease. Proc. Nutr. Soc. 68: 249-251 (2009). *

• Sun L, Blair HC, Peng Y, Zaidi N, Adebanjo OA, Wu XB, Wu XY, Iqbal J, Epstein S, Abe E, Moonga BS, Zaidi M. Calcineurin regulates bone formation by the osteoblast. Proc. Natl. Acad. Sci. U.S.A. 102: 17130-17135 (2005). *

• Sundar N, Crimmins R, Swift G. Clinical presentation and incidence of complications in patients with coeliac disease diagnosed by relative screening. Postgrad. Med. J. 83: 273-276 (2007). *

• Suwa A, Saito E, Wakabayashi T, Suzuki Y. Secondary osteoporosis. Pathologic condition of osteoporosis in rheumatoid arthritis. Clin. Calcium 17: 1262-1266 (2007).

• Swanson C, Mellstrom D, Lorentzon M, Vandenput L, Jakobsson J, Rane A, Karlsson M, Ljunggren O, Smith U, Eriksson AL, Belanger A, Labrie F, Ohlsson C. The UDP glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men. J. Clin. Endocrinol. Metab. 92: 4878-4882 (2007). *

• Sylvester FA. Bone abnormalities in gastrointestinal and hepatic disease. Curr. Opin. Pediatr. 11: 402-407 (1999).

• Szalay F. Treatment of primary biliary cirrhosis. J. Physiol. Paris 95: 407-412 (2001).

• Szalay F, Folhoffer A, Horvath A, Csak T, Speer G, Nagy Z, Lakatos P, Horvath C, Habior A, Tornai I, Lakatos PL. Serum leptin, soluble leptin receptor, free leptin index and bone mineral density in patients with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 17: 923-928 (2005).

• Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, Lakatos P. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J. Hepatol. 38: 395-400 (2003). *

• Szumera M, Landowski P, Kaminska B, Gora-Gebka M, Popadiuk S, Renke J. Bone mineral density in inflammatory bowel diseases in children. Med. Wieku. Rozwoj. X: 445-451 (2006).

• Tabb MM, Sun A, Zhou C, Grun F, Errandi J, Romero K, Pham H, Inoue S, Mallick S, Lin M, Forman BM, Blumberg B. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J. Biol. Chem. 278: 43919-43927 (2003). *

• Takahashi T, Morikawa K. Vitamin D receptor agonists: opportunities and challenges in drug discovery. Curr. Top. Med. Chem. 6: 1303-1316 (2006).

• Takasu H, Sugita A, Uchiyama Y, Katagiri N, Okazaki M, Ogata E, Ikeda K. C-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J. Clin. Invest. 116: 528-535 (2006). *

• Takeda S, Kaneoka H, Saito T. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. Mod. Rheumatol. 18: 271-276 (2008). *

• Tamaki J, Iki M, Morita A, Ikeda Y, Sato Y, Kajita E, Kagamimori S, Kagawa Y, Yoneshima H. Peroxisome proliferator-activated receptor gamma polymorphism is related to peak bone mass: the JPOS study. Osteoporos. Int. May 30 [Epub ahead of print] (2009). *

• Tanaka Y. Rheumatoid arthritis and osteoporosis: trends in their treatments. Nippon Rinsho 64: 2359-2366 (2006).

• Tansey MG, Szymkowski DE. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov. Today 14: 1082-1088 (2009).

• Targownik LE, Lix LM, Leung S, Leslie WD. Proton pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology Nov 17 [Epub ahead of print] (2009).

• Tatsumi S, Ishii K, Amizuka N, Li M, Kobayashi T, Kohno K, Ito M, Takeshita S, Ikeda K. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell. Metab. 5: 464-475 (2007). *

• Tau C, Russo R. Severe osteoporosis with vertebral crushes in juvenile dermatomyositis. Effect of oral alendronate therapy. Medicina (B. Aires) 67: 53-56 (2007).

• Teichmann J, Voglau MJ, Lange U. Antibodies to human tissue transglutaminase and alterations of vitamin D metabolism in ankylosing spondylitis and psoriatic arthritis. Rheumatol. Int. Oct 13 [Epub ahead of print] (2009). *

• Terpos E, Voskaridou E. Interactions between osteoclasts, osteoblasts and immune cells: implications for the pathogenesis of bone loss in thalassemia. Pediatr. Endocrinol. Rev. 6 Suppl. 1: 94-106 (2008).

• Teyssier C, Gallet M, Rabier B, Monfoulet L, Dine J, Macari C, Espallergues J, Horard B, Giguere V, Cohen-Solal M, Chassande O, Vanacker JM. Absence of ERRalpha in female mice confers resistance to bone loss induced by age or estrogen-deficiency. PLoS One 4: e7942 (2009). *

• Tezuka K, Denhardt DT, Rodan GA, Harada S. Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor. J. Biol. Chem. 271: 22713-22717 (1996). *

• The Genetic Factors for Osteoporosis (GEFOS) Consortium, Rivadeneira F, Styrkarsdottir U, Estrada K, Halldorsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet. 41: 1199-1206 (2009). *

• Thiele K, Buttgereit F, Huscher D, Zink A. Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. Arthritis Rheum. 53: 740-747 (2005). *

• Thijssen JH. Gene polymorphisms involved in the regulation of bone quality. Gynecol. Endocrinol. 22: 131-139 (2006).

• Thompson PD, Hsieh JC, Whitfield GK, Haussler CA, Jurutka PW, Galligan MA, Tillman JB, Spindler SR, Haussler MR. Vitamin D receptor displays DNA binding and transactivation as a heterodimer with the retinoid X receptor, but not with the thyroid hormone receptor. J. Cell. Biochem. 75: 462-480 (1999). *

• Thurston RD, Larmonier CB, Majewski PM, Ramalingam R, Midura-Kiela M, Laubitz D, Vandewalle A, Besselsen DG, Muhlbauer M, Jobin C, Kiela PR, Ghishan FK. Downregulation of aging-related Klotho gene in experimental colitis: the role of TNF and IFN-gamma. Gastroenterology Dec 14 [Epub ahead of print] (2009). *

• Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut, inflammation and osteoporosis: basic and clinical concepts. Gut 57: 684-694 (2008).

• Tissandie E, Gueguen Y, Lobaccaro JM, Aigueperse J, Souidi M. Vitamin D: metabolism, regulation and associated diseases. Med. Sci (Paris) 22: 1095-1100 (2006).

• Todhunter CE, Sutherland-Craggs A, Bartram SA, Donaldson P, Daly A, Francis R, Mansfield JC, Thompson NP. The influence of IL6, COL1A1 and VDR gene polymorphisms on bone mineral density in Crohn's disease. Gut 54: 1579-1584 (2005). *

• Toussirot E, Royet O, Wendling D. Aetiologic features of osteoporosis in male patients aged less than 50 years: study of 28 cases with a comparative series of 30 patients over the age of 50. Rev. Med. Interne. 19: 479-485 (1998).

• Toussirot E, Wendling D. Antiinflammatory treatment with bisphosphonates in ankylosing spondylitis. Curr. Opin. Rheumatol. 19: 340-345 (2007).

• Towers R, Naftali T, Gabay G, Carlebach M, Klein A, Novis B. High levels of glucocorticoid receptors in patients with active Crohn’s disease may predict steroid resistance. Clin. Exp. Immunol. 141: 357-362 (2005). *

• Tran BN, Nguyen ND, Center JR, Eisman JA, Nguyen TV. Enhancement of absolute fracture risk prognosis with genetic marker: the collagen I alpha 1 gene. Calcif. Tissue Int. Sep 30 [Epub ahead of print] (2009).

• Tran TT. Liver transplantation: a clinical update. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *

• Trautwein C, Possienke M, Schlitt HJ, Boker KH, Horn R, Raab R, Manns MP, Brabant G. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation. Am. J. Gastroenterol. 95: 2343-2351 (2000). *

• Trebble TM. Bone turnover and nutritional status in Crohn's disease: relationship to circulating mononuclear cell function and response to fish oil and antioxidants. Proc. Nutr. Soc. 64: 183-191 (2005). *

• Trebble TM, Arden NK, Wootton SA, Calder PC, Mullee MA, Fine DR, Stroud MA. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am. J. Clin. Nutr. 80: 1137-1144 (2004). *

• Triger DR. Autoimmune chronic active hepatitis and primary biliary cirrhosis. Baillieres Clin. Gastroenterol. 3: 21-38 (1989).

• Tseng W, Lu J, Bishop GA, Watson AD, Sage AP, Demer LL, Tintut Y. Regulation of IL-6 expression in osteoblasts by oxidized phospholipids. J. Lipid Res. Nov 11 [Epub ahead of print] (2009). *

• Tsiaousi ET, Hatzitolios AI, Trygonis SK, Savopoulos CG. Malnutrition in end stage liver disease: recommendations and nutritional support. J. Gastroenterol. Hepatol. 23: 527-533 (2008). *

• Tsironi E, Hadjidakis D, Mallas E, Tzathas C, Karamanolis DG, Ladas SD. Comparison of T- and Z-score in identifying risk factors of osteoporosis in inflammatory bowel disease patients. J. Musculoskelet. Neuronal Interact. 8: 79-84 (2008).

• Tsuji N, Takahashi F. Therapeutic agents for disorders of bone and calcium metabolism. ED-71. Clin. Calcium 17: 72-79 (2007).

• Tuohimaa P. Vitamin D and aging. J. Steroid Biochem. Mol. Biol. 114: 78-84 (2009).

• Tuohimaa P, Keisala T, Minasyan A, Cachat J, Kalueff A. Vitamin D, nervous system and aging. Psychoneuroendocrinology 34 Suppl. 1: S278-S286 (2009).

• Turk N, Cukovic-Cavka S, Korsic M, Turk Z, Vucelic B. Proinflammatory cytokines and receptor activator of nuclear factor kappaB-ligand/osteoprotegerin associated with bone deterioration in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 21: 159-166 (2009).

• Turk N, Katelan D, Ukovi-Avka S, Kraljevi I, Kori M, Vuceli B. Discriminatory ability of calcaneal quantitative ultrasound in the assessment of bone status in patients with inflammatory bowel disease. Ultrasound Med. Biol. 33: 863-869 (2007).

• Turner J, Pellerin G, Mager D. Prevalence of metabolic bone disease in children with celiac disease is independent of symptoms at diagnosis. J. Pediatr. Gastroenterol. Nutr. 49: 589-593 (2009).

• Uchida K, Araki T, Toiyama Y, Yoshiyama S, Inoue M, Ikeuchi H, Yanagi H, Miki C, Yamamura T, Kusunoki M. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis. Colon Rectum 49: 74-79 (2006). *

• Uenishi K, Ishida H, Nakamura K. Development of a simple food frequency questionnaire to estimate intakes of calcium and other nutrients for the prevention and management of osteoporosis. J. Nutr. Sci. Vitaminol. (Tokyo) 54: 25-29 (2008). *

• Uitterlinden AG, Ralston SH, Brandi ML, Carey AH, Grinberg D, Langdahl BL, Lips P, Lorenc R, Obermayer-Pietsch B, Reeve J, Reid DM, Amidei A, Bassiti A, Bustamante M, Husted LB, Diez-Perez A, Dobnig H, Dunning AM, Enjuanes A, Fahrleitner-Pammer A, et al. The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann. Intern. Med. 145: 255-264 (2006). *

• Uitterlinden AG, van Meurs JB, Rivadeneira F, Pols HA. Identifying genetic risk factors for osteoporosis. J. Musculoskelet. Neuronal Interact. 6: 16-26 (2006).

• Uysal AR, Sahin M, Gursoy A, Gullu S. Vitamin D receptor gene polymorphism and osteoporosis in the Turkish population. Genet. Test. 12: 591-594 (2008).

• Vahedi H, Momtahen S, Olfati G, Abtahi A, Hosseini S, Kazzazi AS, Khademi H, Rashtak S, Khaleghnejad R, Tabrizian T, Hamidi Z, Nouraie M, Malekzadeh F, Merat S, Nasseri-Moghaddam S, Sotoudehmanesh R, Larijani B. A case-control study on risk factors of osteoporosisin patients with Crohn's disease. Arch. Iran. Med. 12: 570-575 (2009).

• Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am. J. Gastroenterol. 94: 878-883 (1999). *

• Valero C, Alonso MA, Zarrabeitia MT, Viadero C, Hernandez JL, Riancho JA. MTHFR C677T polymorphism and osteoporotic fractures. Horm. Metab. Res. 39: 543-547 (2007).

• Van Bodegraven AA, Pena AS. Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 201-212 (2003).

• van Daele PL, Pols HA. Disorders of bone metabolism in gastrointestinal and hepatic diseases. Ned. Tijdschr. Geneeskd. 144: 462-467 (2000).

• van Hogezand RA, Banffer D, Zwinderman AH, McCloskey EV, Griffioen G, Hamdy NA. Ileum resection is the most predictive factor for osteoporosis in patients with Crohn's disease. Osteoporos. Int. 17: 535-542 (2006).

• Van Hogezand RA, Hamdy NA. Skeletal morbidity in inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 243: 59-64 (2006). *

• van Meurs JB, Trikalinos TA, Ralston SH, Balcells S, Brandi ML, Brixen K, Kiel DP, Langdahl BL, Lips P, Ljunggren O, Lorenc R, Obermayer-Pietsch B, Ohlsson C, Pettersson U, Reid DM, Rousseau F, Scollen S, Van Hul W, Agueda L, Akesson K, et al. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA 299: 1277-1290 (2008). *

• Van Schaik FD, Verhagen MA, Siersema PD, Oldenburg B. High prevalence of low bone mineral density in patients with inflammatory bowel disease in the setting of a peripheral Dutch hospital. Journal of Crohn's and Colitis 2: 208-213 (2008).

• van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 79: 129-137 (2006). *

• van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK. Inflammatory bowel disease and the risk of fracture. Gastroenterology 125: 1591-1597 (2003). *

• Van Winckel M, De Bruyne R, Van De Velde S, Van Biervliet S. Vitamin K, an update for the paediatrician. Eur. J. Pediatr. 168: 127-134 (2009). *

• Vasiljeva O, Reinheckel T, Peters C, Turk D, Turk V, Turk B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des. 13: 387-403 (2007).

• Verhoef P, de Groot LC. Dietary determinants of plasma homocysteine concentrations. Semin. Vasc. Med. 5: 110-123 (2005).

• Verkman AS, Galietta LJ. Chloride channels as drug targets. Nat. Rev. Drug Discov. 8: 153-171 (2009).

• Verma A, Jazrawi RP, Ahmed HA, Northfield TC. Prescribing habits in primary biliary cirrhosis: a national survey. Eur. J. Gastroenterol. Hepatol. 11: 817-820 (1999).

• Vestergaard P. Prevalence and pathogenesis of osteoporosis in patients with inflammatory bowel disease. Minerva Med. 95: 469-480 (2004).

• Vestergaard P. Bone loss associated with gastrointestinal disease: prevalence and pathogenesis. Eur. J. Gastroenterol. Hepatol. 15: 851-856 (2003).

• Vestergaard P, Krogh K, Rejnmark L, Laurberg S, Mosekilde L. Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut 46: 176-181 (2000). *

• Vidal Casariego A, de la Cuerda Compes C, Breton Lesmes I, Camblor Alvarez M, Velasco Gimeno C, Garcia Peris P. Avascular necrosis of both hips and knees in a patient with ulcerative colitis treated for a long term with high-dose corticosteroids. Nutr. Hosp. 21: 109-112 (2006).

• Villamin CA, Navarra SV. Clinical manifestations and clinical syndromes of Filipino patients with systemic lupus erythematosus. Mod. Rheumatol. 18: 161-164 (2008). *

• Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur. J. Gastroenterol. Hepatol. 7: 609-614 (1995).

• Vogelsang H, Suk EK, Janisiw M, Stain C, Mayr WR, Panzer S. Calcaneal ultrasound attenuation and vitamin-D-receptor genotypes in celiac disease. Scand. J. Gastroenterol. 35: 172-176 (2000). *

• Von Tirpitz C, Epp S, Klaus J, Mason R, Hawa G, Brinskelle-Schmal N, Hofbauer LC, Adler G, Kratzer W, Reinshagen M. Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease. Eur. J. Gastroenterol. Hepatol. 15: 1165-1170 (2003).

• von Tirpitz C, Klaus J, Bruckel J, Rieber A, Scholer A, Adler G, Bohm BO, Reinshagen M. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 12: 19-24 (2000).

• von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, Boehm BO, Adler G, Reinshagen M. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment. Pharmacol. Ther. 17: 807-816 (2003). *

• Von Tirpitz C, Pischulti G, Klaus J, Rieber A, Bruckel J, Bohm BO, Adler G, Reinshagen M. Pathological bone density in chronic inflammatory bowel diseases - prevalence and risk factors. Z. Gastroenterol. 37: 5-12 (1999).

• von Tirpitz C, Reinshagen M. Management of osteoporosis in patients with gastrointestinal diseases. Eur. J. Gastroenterol. Hepatol. 15: 869-876 (2003).

• von Tirpitz C, Steder-Neukamm U, Glas K, Sander S, Ring C, Klaus J, Reinshagen M. Osteoporosis in inflammatory bowel disease - results of a survey among members of the German Crohn's & Ulcerative Colitis Association. Z. Gastroenterol. 41: 1145-1150 (2003).

• Wagnon JH, Leiman DA, Ayers GD, Schwartz DA. Survey of gastroenterologists' awareness and implementation of AGA guidelines on osteoporosis in inflammatory bowel disease patients: are the guidelines being used and what are the barriers to their use? Inflamm. Bowel Dis. 15: 1082-1089 (2009). *

• Walker SE. Estrogen and autoimmune disease. Clin. Rev. Allergy Immunol. Feb 25 [Epub ahead of print] (2010).

• Walker UA, Tyndall A, Daikeler T. Rheumatic conditions in human immunodeficiency virus infection. Rheumatology (Oxford) 47: 952-959 (2008). *

• Wallis K, Walters JR, Forbes A. Review article: glucagon-like peptide 2 - current applications and future directions. Aliment. Pharmacol. Ther. 25: 365-372 (2007). *

• Walsh MC, Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev. 14: 251-263 (2003).

• Walter M, Moyzes D, Rose M, Neuhaus R, Danzer G, Klapp BF. Psychosomatic interrelations following liver transplantation. Clin. Transplant. 16: 301-305 (2002).

• Walters JR, West J. Analysis of the absolute risks in coeliac disease indicates the importance of the prevention of osteoporosis * Author's reply. Gut 56: 310-311 (2007). *

• Walther F, Fusch C, Radke M, Beckert S, Findeisen A. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J. Pediatr. Gastroenterol. Nutr. 43: 42-51 (2006). *

• Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat. Med. 13: 1496-1503 (2007). *

• Wang KX, Denhardt DT. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 19: 333-345 (2008).

• Wang LT, Zhao YF, Wang X, Xu Y, Chen YC, Zhan HS. Influence of Migu capsule and Strengthening Spleen prescription on the expression of small intestine VDR mRNA in calf muscle on ovariectomy rats. Zhongguo Gu Shang 22: 367-370 (2009).

• Wariaghli G, Mounach A, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, El Maghraoui A. Osteoporosis in chronic liver disease: a case-control study. Rheumatol. Int. Jul 28 [Epub ahead of print] (2009). *

• Watkins BA, Hannon K, Ferruzzi M, Li Y. Dietary PUFA and flavonoids as deterrents for environmental pollutants. J. Nutr. Biochem. 18: 196-205 (2007). *

• Weinstein RS. Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone Jul 7 [Epub ahead of print] (2009). *

• Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360: 53-62 (2009). *

• Weitzmann MN, Pacifici R. T cells: unexpected players in the bone loss induced by estrogen deficiency and in basal bone homeostasis. Ann. N. Y. Acad. Sci. 1116: 360-375 (2007). *

• Weitzmann MN, Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116: 1186-1194 (2006). *

• West J, Logan RF, Card TR, Smith C, Hubbard R. Fracture risk in people with celiac disease: a population-based cohort study. Gastroenterology 125: 429-436 (2003). *

• Whelan AM, Jurgens TM, Bowles SK. Natural health products in the prevention and treatment of osteoporosis: systematic review of randomized controlled trials. Ann. Pharmacother. 40: 836-849 (2006).

• Wick JY. Spontaneous fracture: multiple causes. Consult. Pharm. 24: 100-112 (2009).

• Wiercinska-Drapalo A, Jaroszewicz J, Tarasow E, Flisiak R, Prokopowicz D. Transforming growth factor beta(1) and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients. Prostaglandins Other Lipid Mediat. 78: 160-168 (2005).

• Williams FM, Spector T. The genetics of osteoporosis. Acta Reumatol. Port. 32: 231-240 (2007). *

• Williams FM, Spector TD. Recent advances in the genetics of osteoporosis. J. Musculoskelet. Neuronal Interact. 6: 27-35 (2006).

• Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, Crutchfield M, D'Agostino D, Jannausch M. Bone mineral density and its change in white women: estrogen and vitamin D receptor genotypes and their interaction. J. Bone Miner. Res. 13: 695-705 (1998).

• Wills MR, Savory J. Vitamin D metabolism and chronic liver disease. Ann. Clin. Lab. Sci. 14: 189-197 (1984).

• Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin. Infect. Dis. 34: 204-209 (2002). *

• Wolfhagen FH, van Buuren HR, Vleggaar FP, Schalm SW. Management of osteoporosis in primary biliary cirrhosis. Best Pract. Res. Clin. Gastroenterol. 14: 629-641 (2000).

• Wolfraim LA. Treating autoimmune diseases through restoration of antigen-specific immune tolerance. Arch. Immunol. Ther. Exp. (Warsz.) 54: 1-13 (2006).

• Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome. Nat. Clin. Pract. Rheumatol. 2: 28-34 (2006). *

• Wu JJ, Schiff KR. Sarcoidosis. Am. Fam. Physician 70: 312-322 (2004). *

• Wu Z, Ma HM, Kukita T, Nakanishi Y, Nakanishi H. Phosphatidylserine-containing liposomes inhibit the differentiation of osteoclasts and trabecular bone loss. J. Immunol. Feb 22 [Epub ahead of print] (2010).

• Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br. J. Pharmacol. 158: 395-412 (2009). *

• Wu-Wong JR. Are vitamin D receptor activators useful for the treatment of thrombosis? Curr. Opin. Investig. Drugs 10: 919-927 (2009).

• Xiong DH, Liu XG, Guo YF, Tan LJ, Wang L, Sha BY, Tang ZH, Pan F, Yang TL, Chen XD, Lei SF, Yerges LM, Zhu XZ, Wheeler VW, Patrick AL, Bunker CH, Guo Y, Yan H, Pei YF, Zhang YP, Levy S, Papasian CJ, Xiao P, Lundberg YW, Recker RR, Liu YZ, Liu YJ, et al. Genome-wide association and follow-up replication studies identified ADAMTS18 and TGFBR3 as bone mass candidate genes in different ethnic groups. Am. J. Hum. Genet. 84: 388-398 (2009). *

• Xiong DH, Shen H, Zhao LJ, Xiao P, Yang TL, Guo Y, Wang W, Guo YF, Liu YJ, Recker RR, Deng HW. Robust and comprehensive analysis of 20 osteoporosis candidate genes by very high-density single-nucleotide polymorphism screen among 405 white nuclear families identified significant association and gene-gene interaction. J. Bone Miner. Res. 21: 1678-1695 (2006). *

• Xiong DH, Wang JT, Wang W, Guo YF, Xiao P, Shen H, Jiang H, Chen Y, Deng H, Drees B, Recker RR, Deng HW. Genetic determination of osteoporosis: lessons learned from a large genome-wide linkage study. Hum. Biol. 79: 593-608 (2007).

• Xiong DH, Xu FH, Liu PY, Shen H, Long JR, Elze L, Recker RR, Deng HW. Vitamin D receptor gene polymorphisms are linked to and associated with adult height. J. Med. Genet. 42: 228-234 (2005). *

• Xiong Q, Han C, Beamer WG, Gu W. A close examination of genes within quantitative trait loci of bone mineral density in whole mouse genome. Crit. Rev. Eukaryot. Gene Expr. 18: 323-343 (2008).

• Yadav VK, Balaji S, Suresh PS, Liu XS, Lu X, Li Z, Guo XE, Mann JJ, Balapure AK, Gershon MD, Medhamurthy R, Vidal M, Karsenty G, Ducy P. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat. Med. Feb 7 [Epub ahead of print] (2010). *

• Yamori Y. Food factors for atherosclerosis prevention: Asian perspective derived from analyses of worldwide dietary biomarkers. Exp. Clin. Cardol. 11: 94-98 (2006). *

• Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, Yan J, Morgan T, Li X, Yuan J, Hock J, Ingram DA, Clapp DW. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J. Clin. Invest. 116: 2880-2891 (2006). *

• Yasuda H. OPG, anti-rANKL antibody. Nippon Rinsho 63: 1647-1653 (2005).

• Ye L, Li YL, Mellstrom K, Mellin C, Bladh LG, Koehler K, Garg N, Garcia Collazo AM, Litten C, Husman B, Persson K, Ljunggren J, Grover G, Sleph PG, George R, Malm J. Thyroid receptor ligands. 1. Agonist ligands selective for the thyroid receptor beta1. J. Med. Chem. 46: 1580-1588 (2003). *

• Young A, Koduri G. Extra-articular manifestations and complications of rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol. 21: 907-927 (2007).

• Yu X, Chen S, Potter OL, Murthy SM, Li J, Pulcini JM, Ohashi N, Winata T, Everett ET, Ingram D, Clapp DW, Hock JM. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 36: 793-802 (2005). *

• Yuen AW, Jablonski NG. Vitamin D: in the evolution of human skin colour. Med. Hypotheses 74: 39-44 (2010).

• Yuksel S, Samli H, Colbay M, Dundar U, Acarturk G, Demir S, Koken T, Aktepe OC, Kavuncu V, Solak M. Increased serum osteoprotegerin levels associated with decreased bone mineral density in familial Mediterranean fever. Tohoku J. Exp. Med. 217: 321-327 (2009). *

• Zadik Z, Sinai T, Zung A, Reifen R. Longitudinal monitoring of bone measured by quantitative multisite ultrasound in patients with Crohn's disease. J. Clin. Gastroenterol. 39: 120-123 (2005).

• Zali M, Bahari A, Firouzi F, Daryani NE, Aghazadeh R, Emam MM, Rezaie A, Shalmani HM, Naderi N, Maleki B, Sayyah A, Bashashati M, Jazayeri H, Zand S. Bone mineral density in Iranian patients with inflammatory bowel disease. Int. J. Colorectal Dis. 21: 758-766 (2006). *

• Zaman G, Jessop HL, Muzylak M, De Souza RL, Pitsillides AA, Price JS, Lanyon LL. Osteocytes use estrogen receptor alpha to respond to strain but their ERalpha content is regulated by estrogen. J. Bone Miner. Res. 21: 1297-1306 (2006). *

• Zambrano-Morales M, Borjas L, Fernandez E, Zabala W, de Romero P, Pineda L, Morales-Machin A. Association of the vitamin D receptor gene BBAAtt haplotype with osteoporosis in post-menopausic women. Invest. Clin. 49: 29-38 (2008).

• Zhang Z, Welte T, Troiano N, Maher SE, Fu XY, Bothwell AL. Osteoporosis with increased osteoclastogenesis in hematopoietic cell-specific STAT3-deficient mice. Biochem. Biophys. Res. Commun. 328: 800-807 (2005). *

• Zhang ZL, He JW, Qin YJ, Hu YQ, Li M, Liu YJ, Zhang H, Hu WW. Association between SNP and haplotypes in PPARGC1 and adiponectin genes and bone mineral density in Chinese nuclear families. Acta Pharmacol. Sin. 28: 287-295 (2007).

• Zhao B, Takami M, Yamada A, Wang X, Koga T, Hu X, Tamura T, Ozato K, Choi Y, Ivashkiv LB, Takayanagi H, Kamijo R. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med. 15: 1066-1071 (2009). *

• Zhao LJ, Xiong DH, Pan F, Liu XG, Recker RR, Deng HW. Polymorphisms of the tumor necrosis factor-alpha receptor 2 gene are associated with obesity phenotypes among 405 Caucasian nuclear families. Hum. Genet. 124: 171-177 (2008). *

• Zhao Q, Shao J, Chen W, Li YP. Osteoclast differentiation and gene regulation. Front. Biosci. 12: 2519-2529 (2007).

• Zhao W, Liu Y, Cahill CM, Yang W, Rogers JT, Huang X. The role of T cells in osteoporosis, an update. Int. J. Clin. Exp. Pathol. 2: 544-552 (2009). *

• Zhou P, Kitaura H, Teitelbaum SL, Krystal G, Ross FP, Takeshita S. SHIP1 negatively regulates proliferation of osteoclast precursors via Akt-dependent alterations in D-type cyclins and p27. J. Immunol. 177: 8777-8784 (2006). *

• Ziegler R. Osteoporosis. Schweiz. Rundsch. Med. Prax. 83: 1051-1055 (1994).

• Zimmermann GR, Avery W, Finelli AL, Farwell M, Fraser CC, Borisy AA. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arthritis Res. Ther. 11: R12 (2009). *

• Zintzaras E, Rodopoulou P, Koukoulis GN. BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and the risk of osteoporosis: a meta-analysis. Dis. Markers 22: 317-326 (2006).

• Zipser RD, Farid M, Baisch D, Patel B, Patel D. Physician awareness of celiac disease. J. Gen. Intern. Med. 20: 644-646 (2005). *

• Zirngibl RA, Chan JS, Aubin JE. Estrogen receptor-related receptor alpha (ERRalpha) regulates osteopontin expression through a non-canonical ERRalpha response element in a cell context-dependent manner. J. Mol. Endocrinol. 40: 61-73 (2008). *

• Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 10: 185-194 (2007).

• Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br. J. Nutr. 89: 552-572 (2003). *

• Zmuda JM, Sheu YT, Moffett SP. Genetic epidemiology of osteoporosis: past, present, and future. Curr. Osteoporos. Rep. 3: 111-115 (2005).

• Zofkova I. Celiac disease and its relation to bone metabolism. Cas. Lek. Cesk. 148: 246-248 (2009).

Number of references = 970

www psc-literature.org